<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'><collection><source>PubTator</source><date></date><key>BioC.key</key><document><id>2927683</id><passage><infon key="name_3">surname:Assassi;given-names:Shervin</infon><infon key="name_2">surname:Tan;given-names:Filemon K</infon><infon key="name_1">surname:Arnett;given-names:Frank C</infon><infon key="name_0">surname:Gourh;given-names:Pravitt</infon><infon key="fpage">550</infon><infon key="issue">3</infon><infon key="year">2010</infon><infon key="article-id_publisher-id">annrheumdis116434</infon><infon key="article-id_doi">10.1136/ard.2009.116434</infon><infon key="type">front</infon><infon key="volume">69</infon><infon key="license">This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.</infon><infon key="name_10">surname:Agarwal;given-names:Sandeep K</infon><infon key="section_type">TITLE</infon><infon key="name_9">surname:Mayes;given-names:Maureen D</infon><infon key="name_8">surname:Reveille;given-names:John D</infon><infon key="name_7">surname:Draeger;given-names:Hilda</infon><infon key="lpage">555</infon><infon key="name_6">surname:McNearney;given-names:Terry</infon><infon key="name_5">surname:Paz;given-names:Gene</infon><infon key="name_4">surname:Divecha;given-names:Dipal</infon><infon key="article-id_pmc">2927683</infon><infon key="article-id_pmid">19778912</infon><offset>0</offset><text>Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis</text><annotation id="26117"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="15" length="6" /><text>TNFSF4</text></annotation><annotation id="26118"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="23" length="5" /><text>OX40L</text></annotation><annotation id="26119"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="67" length="18" /><text>systemic sclerosis</text></annotation></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>86</offset><text>Objective</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>96</offset><text>It is increasingly being appreciated that multiple autoimmune diseases share common susceptibility genes. The tumour necrosis factor ligand superfamily member 4 gene (TNFSF4, OX40L), which encodes for the T cell costimulatory molecule OX40 ligand, has been identified as a susceptibility gene for the development of systemic lupus erythematosus (SLE). Accordingly, the aim of the current study was to investigate the possible association of the TNFSF4 gene region with systemic sclerosis (SSc), an autoimmune disease that leads to the development of cutaneous and visceral fibrosis.</text><annotation id="26120"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="263" length="6" /><text>TNFSF4</text></annotation><annotation id="26121"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="271" length="5" /><text>OX40L</text></annotation><annotation id="26122"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="331" length="11" /><text>OX40 ligand</text></annotation><annotation id="26123"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="541" length="6" /><text>TNFSF4</text></annotation><annotation id="26124"><infon key="identifier">MESH:D005355</infon><infon key="type">Disease</infon><location offset="646" length="31" /><text>cutaneous and visceral fibrosis</text></annotation><annotation id="26125"><infon key="identifier">MESH:D001327</infon><infon key="type">Disease</infon><location offset="594" length="18" /><text>autoimmune disease</text></annotation><annotation id="26126"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="442" length="3" /><text>SLE</text></annotation><annotation id="26127"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="412" length="28" /><text>systemic lupus erythematosus</text></annotation><annotation id="26128"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="585" length="3" /><text>SSc</text></annotation><annotation id="26129"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="565" length="18" /><text>systemic sclerosis</text></annotation><annotation id="26130"><infon key="identifier">MESH:D001327</infon><infon key="type">Disease</infon><location offset="147" length="19" /><text>autoimmune diseases</text></annotation></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>679</offset><text>Methods</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>687</offset><text>A total of 9 single nucleotide polymorphisms (SNPs) in the TNFSF4 gene region, previously associated with susceptibility to SLE, were tested for association with SSc in a collection of 1059 patients with SSc and 698 controls.</text><annotation id="26131"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="746" length="6" /><text>TNFSF4</text></annotation><annotation id="26132"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="877" length="8" /><text>patients</text></annotation><annotation id="26133"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="891" length="3" /><text>SSc</text></annotation><annotation id="26134"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="811" length="3" /><text>SLE</text></annotation><annotation id="26135"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="849" length="3" /><text>SSc</text></annotation></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>913</offset><text>Results</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>921</offset><text>Case-control comparisons revealed a significant association between susceptibility to SSc and the minor alleles at SNPs rs1234314 (OR 1.20, 95% CI 1.04 to 1.4, pFDR=0.019), rs2205960 (OR 1.24, 95% CI 1.10 to 1.50, pFDR=0.019) and rs844648 (OR 1.16, 95% CI 1.01 to 1.30, pFDR=0.032). The minor allele at rs844644 was protective (OR 0.84, 95% CI 0.70 to 0.97, pFDR=0.038). Analysis of subsets of patients with SSc demonstrated significant associations of the TNFSF4 SNPs with limited and diffuse SSc as well as specific SNPs that were associated with SSc-associated autoantibodies. Finally, the analyses suggest a potential interaction between two TNFSF4 SNPs, rs2205960 and rs844648, with regards to SSc susceptibility.</text><annotation id="26136"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="1378" length="6" /><text>TNFSF4</text></annotation><annotation id="26137"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="1567" length="6" /><text>TNFSF4</text></annotation><annotation id="26138"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="1470" length="3" /><text>SSc</text></annotation><annotation id="26139"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="1007" length="3" /><text>SSc</text></annotation><annotation id="26140"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="1094" length="9" /><text>rs2205960</text></annotation><annotation id="26141"><infon key="identifier">tmVar:rs844648;VariantGroup:11;CorrespondingGene:100506023;RS#:844648;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="1594" length="8" /><text>rs844648</text></annotation><annotation id="26142"><infon key="identifier">tmVar:rs1234314;VariantGroup:10;OriginalGene:22164;CorrespondingGene:7292;RS#:1234314;CorrespondingSpecies:10090</infon><infon key="type">SNP</infon><location offset="1041" length="9" /><text>rs1234314</text></annotation><annotation id="26143"><infon key="identifier">tmVar:rs844648;VariantGroup:11;CorrespondingGene:100506023;RS#:844648;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="1151" length="8" /><text>rs844648</text></annotation><annotation id="26144"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="1620" length="3" /><text>SSc</text></annotation><annotation id="26145"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="1329" length="3" /><text>SSc</text></annotation><annotation id="26146"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="1580" length="9" /><text>rs2205960</text></annotation><annotation id="26147"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="1415" length="3" /><text>SSc</text></annotation><annotation id="26148"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="1315" length="8" /><text>patients</text></annotation><annotation id="26149"><infon key="identifier">tmVar:rs844644;VariantGroup:8;CorrespondingGene:100506023;RS#:844644;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="1224" length="8" /><text>rs844644</text></annotation></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1640</offset><text>Conclusions</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1652</offset><text>Polymorphisms in the TNFSF4 gene region are associated with susceptibility to SSc and its clinical and autoantibody subsets. TNFSF4 may be another gene that confers risk to multiple autoimmune diseases.</text><annotation id="26150"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="1673" length="6" /><text>TNFSF4</text></annotation><annotation id="26151"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="1777" length="6" /><text>TNFSF4</text></annotation><annotation id="26152"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="1730" length="3" /><text>SSc</text></annotation><annotation id="26153"><infon key="identifier">MESH:D001327</infon><infon key="type">Disease</infon><location offset="1834" length="19" /><text>autoimmune diseases</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1855</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1868</offset><text>Recently, a number of reports have identified genes that are associated with the development of multiple autoimmune diseases suggesting that autoimmune diseases share genetic risk factors. For example, PTPN22 has been associated with the development of type I diabetes mellitus (TIDM), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). STAT4 is a susceptibility gene for the development of SLE and RA. Together these studies implicate dysregulation of common immune pathways due to polymorphisms in several genes in the development of a variety of autoimmune diseases.</text><annotation id="26154"><infon key="identifier">26191</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7498</infon><location offset="2070" length="6" /><text>PTPN22</text></annotation><annotation id="26155"><infon key="identifier">6775</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20679</infon><location offset="2220" length="5" /><text>STAT4</text></annotation><annotation id="26156"><infon key="identifier">MESH:D001172</infon><infon key="type">Disease</infon><location offset="2282" length="2" /><text>RA</text></annotation><annotation id="26157"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="2184" length="28" /><text>systemic lupus erythematosus</text></annotation><annotation id="26158"><infon key="identifier">MESH:D001327</infon><infon key="type">Disease</infon><location offset="2009" length="19" /><text>autoimmune diseases</text></annotation><annotation id="26159"><infon key="identifier">MESH:D001327</infon><infon key="type">Disease</infon><location offset="2432" length="19" /><text>autoimmune diseases</text></annotation><annotation id="26160"><infon key="identifier">MESH:D001327</infon><infon key="type">Disease</infon><location offset="1973" length="19" /><text>autoimmune diseases</text></annotation><annotation id="26161"><infon key="identifier">MESH:D003922</infon><infon key="type">Disease</infon><location offset="2147" length="4" /><text>TIDM</text></annotation><annotation id="26162"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="2214" length="3" /><text>SLE</text></annotation><annotation id="26163"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="2274" length="3" /><text>SLE</text></annotation><annotation id="26164"><infon key="identifier">MESH:D001172</infon><infon key="type">Disease</infon><location offset="2176" length="2" /><text>RA</text></annotation><annotation id="26165"><infon key="identifier">MESH:D001172</infon><infon key="type">Disease</infon><location offset="2154" length="20" /><text>rheumatoid arthritis</text></annotation><annotation id="26166"><infon key="identifier">MESH:D003922</infon><infon key="type">Disease</infon><location offset="2121" length="24" /><text>type I diabetes mellitus</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2453</offset><text>The tumour necrosis factor ligand superfamily member 4 gene (TNFSF4, OX40L), which encodes for the costimulatory molecule OX40 ligand, has been identified as a susceptibility gene for SLE in multiple studies. To date, polymorphisms in TNFSF4 also have been associated with atherosclerosis, but there are no published reports of the association of TNFSF4 with autoimmune diseases such as RA, TIDM, or systemic sclerosis (scleroderma, SSc).</text><annotation id="26167"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="2514" length="6" /><text>TNFSF4</text></annotation><annotation id="26168"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="2522" length="5" /><text>OX40L</text></annotation><annotation id="26169"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="2575" length="11" /><text>OX40 ligand</text></annotation><annotation id="26170"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="2688" length="6" /><text>TNFSF4</text></annotation><annotation id="26171"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="2800" length="6" /><text>TNFSF4</text></annotation><annotation id="26172"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="2886" length="3" /><text>SSc</text></annotation><annotation id="26173"><infon key="identifier">MESH:D003922</infon><infon key="type">Disease</infon><location offset="2844" length="4" /><text>TIDM</text></annotation><annotation id="26174"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="2873" length="11" /><text>scleroderma</text></annotation><annotation id="26175"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="2637" length="3" /><text>SLE</text></annotation><annotation id="26176"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="2726" length="15" /><text>atherosclerosis</text></annotation><annotation id="26177"><infon key="identifier">MESH:D001327</infon><infon key="type">Disease</infon><location offset="2812" length="19" /><text>autoimmune diseases</text></annotation><annotation id="26178"><infon key="identifier">MESH:D001172</infon><infon key="type">Disease</infon><location offset="2840" length="2" /><text>RA</text></annotation><annotation id="26179"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="2853" length="18" /><text>systemic sclerosis</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2892</offset><text>SSc is a chronic multisystem disease clinically characterised by progressive fibrosis in the skin and internal organs. Pathologically, SSc exhibits three cardinal features: inflammation and autoimmunity, vasculopathy and excessive extracellular matrix deposition. The immune alterations that lead to the development of SSc are unknown, but multiple lines of evidence suggest that SSc may share common immune alterations with SLE. For example, similar to SLE, patients with SSc have a myriad of circulating antinuclear antibodies. Furthermore, peripheral blood cells from a subset of patients with SLE and SSc have a pattern of upregulation of type I interferon associated gene transcripts. These data now have been extended at the genetic level where SLE and SSc have been associated with polymorphisms in the interferon regulatory factor 5 (IRF5) gene, STAT4, PTPN22 and FAS. </text><annotation id="26180"><infon key="identifier">3663</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8088</infon><location offset="3702" length="30" /><text>interferon regulatory factor 5</text></annotation><annotation id="26181"><infon key="identifier">3663</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8088</infon><location offset="3734" length="4" /><text>IRF5</text></annotation><annotation id="26182"><infon key="identifier">6775</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20679</infon><location offset="3746" length="5" /><text>STAT4</text></annotation><annotation id="26183"><infon key="identifier">26191</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7498</infon><location offset="3753" length="6" /><text>PTPN22</text></annotation><annotation id="26184"><infon key="identifier">355</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">27</infon><location offset="3764" length="3" /><text>FAS</text></annotation><annotation id="26185"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="2892" length="3" /><text>SSc</text></annotation><annotation id="26186"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="3475" length="8" /><text>patients</text></annotation><annotation id="26187"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="3497" length="3" /><text>SSc</text></annotation><annotation id="26188"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="3351" length="8" /><text>patients</text></annotation><annotation id="26189"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="3643" length="3" /><text>SLE</text></annotation><annotation id="26190"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="3272" length="3" /><text>SSc</text></annotation><annotation id="26191"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="3027" length="3" /><text>SSc</text></annotation><annotation id="26192"><infon key="identifier">MESH:D000090122</infon><infon key="type">Disease</infon><location offset="3096" length="12" /><text>vasculopathy</text></annotation><annotation id="26193"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="3365" length="3" /><text>SSc</text></annotation><annotation id="26194"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="3211" length="3" /><text>SSc</text></annotation><annotation id="26195"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="3346" length="3" /><text>SLE</text></annotation><annotation id="26196"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="3489" length="3" /><text>SLE</text></annotation><annotation id="26197"><infon key="identifier">MESH:D001327</infon><infon key="type">Disease</infon><location offset="3082" length="12" /><text>autoimmunity</text></annotation><annotation id="26198"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="3065" length="12" /><text>inflammation</text></annotation><annotation id="26199"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="3317" length="3" /><text>SLE</text></annotation><annotation id="26200"><infon key="identifier">MESH:D005355</infon><infon key="type">Disease</infon><location offset="2969" length="8" /><text>fibrosis</text></annotation><annotation id="26201"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="3651" length="3" /><text>SSc</text></annotation><annotation id="26202"><infon key="identifier">MESH:D004194</infon><infon key="type">Disease</infon><location offset="2921" length="7" /><text>disease</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3770</offset><text>Given the association of polymorphisms in the TNFSF4 gene region with susceptibility to SLE as well as the potential common alterations in immune function and related genes between SLE and SSc, the current study sought to determine if polymorphisms in the TNFSF4 gene region are associated with SSc susceptibility in a large case-control study of North American Caucasian patients with SSc and healthy controls.</text><annotation id="26203"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="3816" length="6" /><text>TNFSF4</text></annotation><annotation id="26204"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="4026" length="6" /><text>TNFSF4</text></annotation><annotation id="26205"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="3951" length="3" /><text>SLE</text></annotation><annotation id="26206"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="4142" length="8" /><text>patients</text></annotation><annotation id="26207"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="3959" length="3" /><text>SSc</text></annotation><annotation id="26208"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="3858" length="3" /><text>SLE</text></annotation><annotation id="26209"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="4065" length="3" /><text>SSc</text></annotation><annotation id="26210"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="4156" length="3" /><text>SSc</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>4182</offset><text>Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>4190</offset><text>Patients with SSc and controls</text><annotation id="26211"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="4190" length="8" /><text>Patients</text></annotation><annotation id="26212"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="4204" length="3" /><text>SSc</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4221</offset><text>A total of 1059 Caucasian patients with SSc and 698 healthy Caucasian controls from the Scleroderma Family Registry and DNA Repository and the University of Texas Rheumatology Division, dating from 1986 to present, including the Genetics versus Environment in Scleroderma Outcomes Study (GENISOS) formed the current cohort. All patients with SSc fulfilled American College of Rheumatology (ACR) preliminary criteria for disease classification or had at least three of the five CREST (for 'Calcinosis, Raynaud's phenomenon, Eesophageal dysfunction, Sclerodactyly and Telangiectasias') features. Patients were not excluded if they had symptoms of myositis or Sjogren's syndrome. Patients in the registry were excluded if they met ACR criteria for SLE. In the division samples, one patient was subsequently diagnosed as having SLE. The patients were classified as limited or diffuse cutaneous SSc according to published criteria. All participants provided written informed consent and the study was approved by the Committee for the Protection of Human Subjects of The University of Texas Health Science Centre at Houston.</text><annotation id="26213"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="5152" length="12" /><text>participants</text></annotation><annotation id="26214"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="5265" length="5" /><text>Human</text></annotation><annotation id="26215"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="5000" length="7" /><text>patient</text></annotation><annotation id="26216"><infon key="identifier">MESH:D045743</infon><infon key="type">Disease</infon><location offset="5082" length="32" /><text>limited or diffuse cutaneous SSc</text></annotation><annotation id="26217"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="4966" length="3" /><text>SLE</text></annotation><annotation id="26218"><infon key="identifier">MESH:D002114</infon><infon key="type">Disease</infon><location offset="4710" length="10" /><text>Calcinosis</text></annotation><annotation id="26219"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="4898" length="8" /><text>Patients</text></annotation><annotation id="26220"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="4549" length="8" /><text>patients</text></annotation><annotation id="26221"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="4563" length="3" /><text>SSc</text></annotation><annotation id="26222"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="4309" length="11" /><text>Scleroderma</text></annotation><annotation id="26223"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="5054" length="8" /><text>patients</text></annotation><annotation id="26224"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="4261" length="3" /><text>SSc</text></annotation><annotation id="26225"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="4815" length="8" /><text>Patients</text></annotation><annotation id="26226"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="4247" length="8" /><text>patients</text></annotation><annotation id="26227"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="4481" length="11" /><text>Scleroderma</text></annotation><annotation id="26228"><infon key="identifier">MESH:D012859</infon><infon key="type">Disease</infon><location offset="4878" length="18" /><text>Sjogren's syndrome</text></annotation><annotation id="26229"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="5045" length="3" /><text>SLE</text></annotation><annotation id="26230"><infon key="identifier">MESH:D017675</infon><infon key="type">Disease</infon><location offset="4769" length="33" /><text>Sclerodactyly and Telangiectasias</text></annotation><annotation id="26231"><infon key="identifier">MESH:D011928</infon><infon key="type">Disease</infon><location offset="4722" length="20" /><text>Raynaud's phenomenon</text></annotation><annotation id="26232"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="4744" length="23" /><text>Eesophageal dysfunction</text></annotation><annotation id="26233"><infon key="identifier">MESH:D009220</infon><infon key="type">Disease</infon><location offset="4866" length="8" /><text>myositis</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5345</offset><text>Autoantibody analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5367</offset><text>Testing for antinuclear antibodies was performed using indirect immunofluorescence (IIF) and HEp-2 cells as antigen substrate (Antibodies Inc, Davis, California, USA). Anti-centromere antibodies (ACA) were determined by their distinctive IIF pattern on HEp-2 cells. Autoantibodies to topoisomerase I (ATA) were determined by passive immunodiffusion (Inova Diagnostics, San Diego, California, USA). Anti-RNA polymerase III antibodies (ARA) were determined by enzyme-linked immunoassay (MBL, Nagoya, Japan).</text><annotation id="26234"><infon key="identifier">CVCL:1906</infon><infon key="type">CellLine</infon><location offset="5460" length="5" /><text>HEp-2</text></annotation><annotation id="26235"><infon key="identifier">CVCL:1906</infon><infon key="type">CellLine</infon><location offset="5620" length="5" /><text>HEp-2</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5873</offset><text>SNP selection and genotyping</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5902</offset><text>Single nucleotide polymorphisms (SNPs) in the TNFSF4 gene region were selected based on TNFSF4 variants identified in two independent candidate gene studies in SLE. Genomic DNA was extracted from peripheral blood with the PureGene genomic DNA isolation kit (Gentra Systems, Minneapolis, Minnesota, USA). The following TNFSF4 SNPs were genotyped: rs1234314, rs1234315, rs2205960, rs844644, rs12039904, rs2795288, rs844648, rs844665 and rs10912580, using an ABI TaqMan SNP genotyping assay from Applied Biosystems (Foster City, California, USA). ABI 7900HT real-time thermocycler was used to perform the plate reading. Automated allele calling was performed by allelic discrimination plots using SDS V.2.3 software (Applied Biosystems). Multiple positive (Centre d'Etude du Polymorphisme Humain (CEPH) samples) and negative controls were used in each genotyping assay and allele calls were verified with HapMap data for validation.</text><annotation id="26236"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="5948" length="6" /><text>TNFSF4</text></annotation><annotation id="26237"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="5990" length="6" /><text>TNFSF4</text></annotation><annotation id="26238"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="6220" length="6" /><text>TNFSF4</text></annotation><annotation id="26239"><infon key="identifier">tmVar:rs2795288;VariantGroup:12;CorrespondingGene:100506023;RS#:2795288;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="6303" length="9" /><text>rs2795288</text></annotation><annotation id="26240"><infon key="identifier">tmVar:rs844644;VariantGroup:8;CorrespondingGene:100506023;RS#:844644;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="6281" length="8" /><text>rs844644</text></annotation><annotation id="26241"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="6270" length="9" /><text>rs2205960</text></annotation><annotation id="26242"><infon key="identifier">tmVar:rs1234314;VariantGroup:10;OriginalGene:22164;CorrespondingGene:7292;RS#:1234314;CorrespondingSpecies:10090</infon><infon key="type">SNP</infon><location offset="6248" length="9" /><text>rs1234314</text></annotation><annotation id="26243"><infon key="identifier">tmVar:rs844648;VariantGroup:11;CorrespondingGene:100506023;RS#:844648;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="6314" length="8" /><text>rs844648</text></annotation><annotation id="26244"><infon key="identifier">tmVar:rs1234315;VariantGroup:4;OriginalGene:22164;CorrespondingGene:7292;RS#:1234315;CorrespondingSpecies:10090</infon><infon key="type">SNP</infon><location offset="6259" length="9" /><text>rs1234315</text></annotation><annotation id="26245"><infon key="identifier">MESH:D012967</infon><infon key="type">Chemical</infon><location offset="6596" length="3" /><text>SDS</text></annotation><annotation id="26246"><infon key="identifier">tmVar:rs844665;VariantGroup:7;CorrespondingGene:100506023;RS#:844665;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="6324" length="8" /><text>rs844665</text></annotation><annotation id="26247"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="6062" length="3" /><text>SLE</text></annotation><annotation id="26248"><infon key="identifier">tmVar:rs12039904;VariantGroup:5;CorrespondingGene:100506023;RS#:12039904;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="6291" length="10" /><text>rs12039904</text></annotation><annotation id="26249"><infon key="identifier">tmVar:rs10912580;VariantGroup:0;CorrespondingGene:100506023;RS#:10912580;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="6337" length="10" /><text>rs10912580</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6834</offset><text>Statistical analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6855</offset><text>Statistical analyses were performed using SAS V.9.1.3 (SAS Institute Inc, Cary, North Carolina, USA) software. Hardy-Weinberg equilibrium (HWE) testing was performed using the exact test for HWE. Allelic and genotypic associations were calculated using the standard Pearson chi2 test or Fisher exact test. Statistical significance was considered at p&lt;0.05 after correcting for multiple comparisons using a false discovery rate method (pFDR). Logistic regression analysis was performed to confirm these associations. Measures of pairwise linkage disequilibrium (LD) were determined using Haploview (Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA). SAS was used for overall ('omnibus test') haplotype frequency tests as well as for haplotype-specific tests. The 'omnibus test' was evaluated to detect differences in overall haplotype frequency profiles between SSc and controls. Classification and regression tree (CART) analysis was performed to explore interactions between SNPs (CART V.6.0; Salford Systems, San Diego, California, USA) using gender and SNPs of TNFSF4 as nominal categorical variables to predict the outcome of SSc. Logistic regression analysis was performed to verify the SNP interaction observed in CART analysis.</text><annotation id="26250"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="7945" length="6" /><text>TNFSF4</text></annotation><annotation id="26251"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="7742" length="3" /><text>SSc</text></annotation><annotation id="26252"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="8011" length="3" /><text>SSc</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>8125</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>8133</offset><text>Linkage disequilibrium in the TNFSF4 gene region in healthy controls</text><annotation id="26253"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="8163" length="6" /><text>TNFSF4</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>8202</offset><text>A candidate gene association study was conducted using 1059 Caucasian patients with SSc and 698 healthy controls. Clinical and serological data for the patients with SSc are presented in table 1. Nine TNFSF4 SNPs previously associated with susceptibility to SLE were genotyped in patients with SSc and controls. All SNPs studied in the TNFSF4 gene region were in HWE in Caucasian controls (see supplementary material). Pairwise LD was calculated by D' and r2 for TNFSF4 SNPs typed in Caucasian controls (figure 1). The TNFSF4 SNPs rs1234314-rs1234315, rs2205960-rs12039904, rs2205960-rs10912580, rs12039904-rs10912580 and rs2795288-rs844648 showed LD in the Caucasian population (r2 &gt;=0.80). Given the tight LD of these SNPs, rs1234315, rs12039904, rs10912580 and rs2795288 were not used in subsequent analyses and the case-control comparisons were performed on the remaining five SNPs tagging the TNFSF4 region.</text><annotation id="26254"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="8403" length="6" /><text>TNFSF4</text></annotation><annotation id="26255"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="8538" length="6" /><text>TNFSF4</text></annotation><annotation id="26256"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="8665" length="6" /><text>TNFSF4</text></annotation><annotation id="26257"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="8721" length="6" /><text>TNFSF4</text></annotation><annotation id="26258"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="9100" length="6" /><text>TNFSF4</text></annotation><annotation id="26259"><infon key="identifier">tmVar:rs10912580;VariantGroup:0;CorrespondingGene:100506023;RS#:10912580;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="8951" length="10" /><text>rs10912580</text></annotation><annotation id="26260"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="8754" length="9" /><text>rs2205960</text></annotation><annotation id="26261"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="8496" length="3" /><text>SSc</text></annotation><annotation id="26262"><infon key="identifier">tmVar:rs844648;VariantGroup:11;CorrespondingGene:100506023;RS#:844648;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="8834" length="8" /><text>rs844648</text></annotation><annotation id="26263"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="8272" length="8" /><text>patients</text></annotation><annotation id="26264"><infon key="identifier">tmVar:rs12039904;VariantGroup:5;CorrespondingGene:100506023;RS#:12039904;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="8939" length="10" /><text>rs12039904</text></annotation><annotation id="26265"><infon key="identifier">tmVar:rs1234314;VariantGroup:10;OriginalGene:22164;CorrespondingGene:7292;RS#:1234314;CorrespondingSpecies:10090</infon><infon key="type">SNP</infon><location offset="8733" length="9" /><text>rs1234314</text></annotation><annotation id="26266"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="8286" length="3" /><text>SSc</text></annotation><annotation id="26267"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="8354" length="8" /><text>patients</text></annotation><annotation id="26268"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="8368" length="3" /><text>SSc</text></annotation><annotation id="26269"><infon key="identifier">tmVar:rs2795288;VariantGroup:12;CorrespondingGene:100506023;RS#:2795288;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="8966" length="9" /><text>rs2795288</text></annotation><annotation id="26270"><infon key="identifier">tmVar:rs1234315;VariantGroup:4;OriginalGene:22164;CorrespondingGene:7292;RS#:1234315;CorrespondingSpecies:10090</infon><infon key="type">SNP</infon><location offset="8928" length="9" /><text>rs1234315</text></annotation><annotation id="26271"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="8776" length="9" /><text>rs2205960</text></annotation><annotation id="26272"><infon key="identifier">tmVar:rs10912580;VariantGroup:0;CorrespondingGene:100506023;RS#:10912580;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="8786" length="10" /><text>rs10912580</text></annotation><annotation id="26273"><infon key="identifier">tmVar:rs12039904;VariantGroup:5;CorrespondingGene:100506023;RS#:12039904;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="8798" length="10" /><text>rs12039904</text></annotation><annotation id="26274"><infon key="identifier">tmVar:rs2795288;VariantGroup:12;CorrespondingGene:100506023;RS#:2795288;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="8824" length="9" /><text>rs2795288</text></annotation><annotation id="26275"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="8460" length="3" /><text>SLE</text></annotation><annotation id="26276"><infon key="identifier">tmVar:rs10912580;VariantGroup:0;CorrespondingGene:100506023;RS#:10912580;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="8809" length="10" /><text>rs10912580</text></annotation><annotation id="26277"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="8482" length="8" /><text>patients</text></annotation><annotation id="26278"><infon key="identifier">tmVar:rs1234315;VariantGroup:4;OriginalGene:22164;CorrespondingGene:7292;RS#:1234315;CorrespondingSpecies:10090</infon><infon key="type">SNP</infon><location offset="8743" length="9" /><text>rs1234315</text></annotation><annotation id="26279"><infon key="identifier">tmVar:rs12039904;VariantGroup:5;CorrespondingGene:100506023;RS#:12039904;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="8764" length="10" /><text>rs12039904</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="type">table_caption</infon><offset>9128</offset><text>Clinical and serological characteristics of patients with systemic sclerosis</text><annotation id="26280"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="9186" length="18" /><text>systemic sclerosis</text></annotation><annotation id="26281"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="9172" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T1.xml</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt; &lt;table frame="hsides" rules="groups"&gt;&lt;colgroup span="1"&gt;&lt;col align="left" span="1"/&gt;&lt;col align="char" char="(" span="1"/&gt;&lt;/colgroup&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;Characteristic&lt;/th&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;Value&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left" colspan="2" rowspan="1"&gt;Controls:&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Gender&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;(N=698)&lt;xref ref-type="table-fn" rid="T1FN1"&gt;*&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Female&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;334 (50.8)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Male&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;323 (49.2)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" colspan="2" rowspan="1"&gt;Systemic sclerosis:&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Gender&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;(N=1059)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Female&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;935 (88.3)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Male&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;124 (11.7)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Skin involvement&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;(N=1004)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Limited systemic sclerosis&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;611 (60.9)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Diffuse systemic sclerosis&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;393 (39.1)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;SSc-associated autoantibodies&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;(N=1059)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Anti-centromere&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;300 (28.3)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Anti-topoisomerase I&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;174 (16.4)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Anti-RNA polymerase III&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;193 (18.2)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Neither anti-centromere, anti-topoisomerase I, or anti-RNA polymerase III&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;392 (37.1)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; </infon><infon key="id">T1</infon><infon key="type">table</infon><offset>9205</offset><text>Characteristic Value   Controls:   Gender (N=698)*    Female 334 (50.8)    Male 323 (49.2)   Systemic sclerosis:   Gender (N=1059)    Female 935 (88.3)    Male 124 (11.7)   Skin involvement (N=1004)    Limited systemic sclerosis 611 (60.9)    Diffuse systemic sclerosis 393 (39.1)   SSc-associated autoantibodies (N=1059)    Anti-centromere 300 (28.3)    Anti-topoisomerase I 174 (16.4)    Anti-RNA polymerase III 193 (18.2)    Neither anti-centromere, anti-topoisomerase I, or anti-RNA polymerase III 392 (37.1)   </text><annotation id="26282"><infon key="identifier">MESH:D012871</infon><infon key="type">Disease</infon><location offset="9378" length="16" /><text>Skin involvement</text></annotation><annotation id="26283"><infon key="identifier">MESH:D045743</infon><infon key="type">Disease</infon><location offset="9448" length="26" /><text>Diffuse systemic sclerosis</text></annotation><annotation id="26284"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="9298" length="18" /><text>Systemic sclerosis</text></annotation><annotation id="26285"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="9488" length="3" /><text>SSc</text></annotation><annotation id="26286"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="9415" length="18" /><text>systemic sclerosis</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="type">table_footnote</infon><offset>9741</offset><text>Values are number (%).</text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="type">table_footnote</infon><offset>9764</offset><text>Missing gender information on 41 controls.</text></passage><passage><infon key="section_type">FIG</infon><infon key="file">ard-69-03-0550-fig1.jpg</infon><infon key="id">F1</infon><infon key="type">fig_caption</infon><offset>9807</offset><text>Linkage disequilibrium (LD) and haplotype block structure of the tumour necrosis factor ligand superfamily member 4 gene (TNFSF4) within healthy controls. Blocks connecting pairs of single nucleotide polymorphisms (SNPs) are shaded according to the strength of the linkage disequilibrium between the SNPs, from 0.0 (white) to 1.0 (black), as measured by the disequilibrium coefficient D'. As an additional measure of strength of LD, r values are given as numerical values within each box.</text><annotation id="26287"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="9929" length="6" /><text>TNFSF4</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>10298</offset><text>TNFSF4 polymorphisms and association with SSc</text><annotation id="26288"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="10298" length="6" /><text>TNFSF4</text></annotation><annotation id="26289"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="10340" length="3" /><text>SSc</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>10344</offset><text>Case-control comparisons for genotypes using the chi2 test demonstrated significant association for multiple SNPs in the TNFSF4 gene region (table 2). These associations remained significant even after controlling for multiple comparisons using the false discovery rate method. Compared to controls, patients with SSc had a higher frequency of the minor allele at rs1234314 (OR 1.2, 95% CI 1.04 to 1.4), rs2205960 (OR 1.2, 95% CI 1.1 to 1.5) and rs844648 (OR 1.2, 95% CI 1.01 to 1.3). The minor allele frequency at rs844648 was less common in patients with SSc compared to controls (OR 0.8, 95% CI 0.7 to 0.97). These data were confirmed using logistic regression analyses after controlling for gender (figure 2). No significant difference was observed between patients with SSc and controls for the rs844665 variant.</text><annotation id="26290"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="10465" length="6" /><text>TNFSF4</text></annotation><annotation id="26291"><infon key="identifier">tmVar:rs844648;VariantGroup:11;CorrespondingGene:100506023;RS#:844648;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="10790" length="8" /><text>rs844648</text></annotation><annotation id="26292"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="10901" length="3" /><text>SSc</text></annotation><annotation id="26293"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="11105" length="8" /><text>patients</text></annotation><annotation id="26294"><infon key="identifier">tmVar:rs844648;VariantGroup:11;CorrespondingGene:100506023;RS#:844648;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="10859" length="8" /><text>rs844648</text></annotation><annotation id="26295"><infon key="identifier">tmVar:rs1234314;VariantGroup:10;OriginalGene:22164;CorrespondingGene:7292;RS#:1234314;CorrespondingSpecies:10090</infon><infon key="type">SNP</infon><location offset="10708" length="9" /><text>rs1234314</text></annotation><annotation id="26296"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="10748" length="9" /><text>rs2205960</text></annotation><annotation id="26297"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="10887" length="8" /><text>patients</text></annotation><annotation id="26298"><infon key="identifier">tmVar:rs844665;VariantGroup:7;CorrespondingGene:100506023;RS#:844665;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="11144" length="8" /><text>rs844665</text></annotation><annotation id="26299"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="10658" length="3" /><text>SSc</text></annotation><annotation id="26300"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="11119" length="3" /><text>SSc</text></annotation><annotation id="26301"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="10644" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">FIG</infon><infon key="file">ard-69-03-0550-fig2.jpg</infon><infon key="id">F2</infon><infon key="type">fig_caption</infon><offset>11162</offset><text>Estimated risk of the tumour necrosis factor ligand superfamily member 4 gene (TNFSF4) single nucleotide polymorphisms (SNPs) in systemic sclerosis (SSc) and subsets of SSc compared to controls by logistic regression controlling for gender.</text><annotation id="26302"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="11241" length="6" /><text>TNFSF4</text></annotation><annotation id="26303"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="11311" length="3" /><text>SSc</text></annotation><annotation id="26304"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="11331" length="3" /><text>SSc</text></annotation><annotation id="26305"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="11291" length="18" /><text>systemic sclerosis</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="type">table_caption</infon><offset>11403</offset><text>Distribution of the tumour necrosis factor ligand superfamily member 4 gene (TNFSF4) SNP genotype in North American Caucasian patients with SSc and normal controls*</text><annotation id="26306"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="11480" length="6" /><text>TNFSF4</text></annotation><annotation id="26307"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="11529" length="8" /><text>patients</text></annotation><annotation id="26308"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="11543" length="3" /><text>SSc</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T2.xml</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt; &lt;table frame="hsides" rules="groups"&gt;&lt;colgroup span="1"&gt;&lt;col align="left" span="1"/&gt;&lt;col align="left" span="1"/&gt;&lt;col align="char" char="." span="1"/&gt;&lt;col align="char" char="." span="1"/&gt;&lt;col align="char" char="." span="1"/&gt;&lt;col align="char" char="." span="1"/&gt;&lt;col align="char" char="(" span="1"/&gt;&lt;/colgroup&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align="left" rowspan="1" colspan="1"/&gt;&lt;th align="left" rowspan="1" colspan="1"/&gt;&lt;th align="left" colspan="2" rowspan="1"&gt;MAF (%)&lt;/th&gt;&lt;th align="left" colspan="3" rowspan="1"&gt;Allelic chi&lt;sup&gt;2&lt;/sup&gt; p value and OR&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;SNP (minor allele)&lt;/th&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;Position (bp)&lt;/th&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;Controls (N=698)&lt;/th&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;SSc (N=1059)&lt;/th&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;p&lt;sub&gt;U&lt;/sub&gt;&lt;/th&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;p&lt;sub&gt;FDR&lt;/sub&gt;&lt;/th&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;OR (95% CI)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;rs1234314 (G)&lt;/td&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;171444015&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;41.3&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;45.8&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.01&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.019&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.20 (1.04 to 1.4)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;rs2205960 (T)&lt;/td&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;171458098&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;21.2&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;25.0&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.01&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.019&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.24 (1.1 to 1.5)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;rs844644 (A)&lt;/td&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;171476118&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;49.1&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;44.7&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.01&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.019&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;0.84 (0.7 to 0.97)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;rs844648 (A)&lt;/td&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;171490486&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;41.4&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;45.2&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.03&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.038&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.16 (1.01 to 1.3)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;rs844665 (T)&lt;/td&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;171515580&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;7.3&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;8.3&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.31&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.31&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.19 (0.9 to 1.5)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; </infon><infon key="id">T2</infon><infon key="type">table</infon><offset>11568</offset><text>  MAF (%) Allelic chi2 p value and OR   SNP (minor allele) Position (bp) Controls (N=698) SSc (N=1059) pU pFDR OR (95% CI)   rs1234314 (G) 171444015 41.3 45.8 0.01 0.019 1.20 (1.04 to 1.4)   rs2205960 (T) 171458098 21.2 25.0 0.01 0.019 1.24 (1.1 to 1.5)   rs844644 (A) 171476118 49.1 44.7 0.01 0.019 0.84 (0.7 to 0.97)   rs844648 (A) 171490486 41.4 45.2 0.03 0.038 1.16 (1.01 to 1.3)   rs844665 (T) 171515580 7.3 8.3 0.31 0.31 1.19 (0.9 to 1.5)   </text><annotation id="26309"><infon key="identifier">tmVar:rs844665;VariantGroup:7;CorrespondingGene:100506023;RS#:844665;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="11954" length="8" /><text>rs844665</text></annotation><annotation id="26310"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="11658" length="3" /><text>SSc</text></annotation><annotation id="26311"><infon key="identifier">tmVar:rs844644;VariantGroup:8;CorrespondingGene:100506023;RS#:844644;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="11824" length="8" /><text>rs844644</text></annotation><annotation id="26312"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="11759" length="9" /><text>rs2205960</text></annotation><annotation id="26313"><infon key="identifier">tmVar:rs844648;VariantGroup:11;CorrespondingGene:100506023;RS#:844648;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="11889" length="8" /><text>rs844648</text></annotation><annotation id="26314"><infon key="identifier">tmVar:rs1234314;VariantGroup:10;OriginalGene:22164;CorrespondingGene:7292;RS#:1234314;CorrespondingSpecies:10090</infon><infon key="type">SNP</infon><location offset="11693" length="9" /><text>rs1234314</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="type">table_footnote</infon><offset>12016</offset><text>Controls are used as reference for all comparisons. bp, base pairs; MAF, minor allele frequency; pFDR, corrected p values using Benjamini and Hochberg false discovery rate method; pU, uncorrected chi2 p values; SSc, systemic sclerosis; SNP, single nucleotide polymorphism.</text><annotation id="26315"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="12232" length="18" /><text>systemic sclerosis</text></annotation><annotation id="26316"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="12227" length="3" /><text>SSc</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12289</offset><text>Analysis of the 5-SNP marker set (rs1234314, rs2205960, rs844644, rs844648, rs844665) in the TNFSF4 revealed 5 out of 28 specific 5-marker haplotypes that were associated with SSc (table 3). Four risk haplotypes were identified: C-G-A-A-C (p&lt;10-4), G-G-C-G-C (p=0.0006), G-G-C-G-T (p&lt;10-4) and G-T-C-G-C (p&lt;10-4). Consistent with the individual SNP 3x2 chi2 analysis, the C-G-A-G-C was found to be protective for the development of SSc (p&lt;10-4). These data support the genetic associations of SNPs in TNFSF4 with SSc susceptibility observed in the case-control comparisons in table 2.</text><annotation id="26317"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="12382" length="6" /><text>TNFSF4</text></annotation><annotation id="26318"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="12790" length="6" /><text>TNFSF4</text></annotation><annotation id="26319"><infon key="identifier">tmVar:rs844648;VariantGroup:11;CorrespondingGene:100506023;RS#:844648;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="12355" length="8" /><text>rs844648</text></annotation><annotation id="26320"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="12802" length="3" /><text>SSc</text></annotation><annotation id="26321"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="12721" length="3" /><text>SSc</text></annotation><annotation id="26322"><infon key="identifier">tmVar:rs844644;VariantGroup:8;CorrespondingGene:100506023;RS#:844644;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="12345" length="8" /><text>rs844644</text></annotation><annotation id="26323"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="12465" length="3" /><text>SSc</text></annotation><annotation id="26324"><infon key="identifier">tmVar:rs844665;VariantGroup:7;CorrespondingGene:100506023;RS#:844665;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="12365" length="8" /><text>rs844665</text></annotation><annotation id="26325"><infon key="identifier">tmVar:rs1234314;VariantGroup:10;OriginalGene:22164;CorrespondingGene:7292;RS#:1234314;CorrespondingSpecies:10090</infon><infon key="type">SNP</infon><location offset="12323" length="9" /><text>rs1234314</text></annotation><annotation id="26326"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="12334" length="9" /><text>rs2205960</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="type">table_caption</infon><offset>12882</offset><text>Haplotype analysis of the 5-SNP marker set in the tumour necrosis factor ligand superfamily member 4 gene (TNFSF4) in Caucasian patients with SSc and controls</text><annotation id="26327"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="12989" length="6" /><text>TNFSF4</text></annotation><annotation id="26328"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="13010" length="8" /><text>patients</text></annotation><annotation id="26329"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="13024" length="3" /><text>SSc</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T3.xml</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt; &lt;table frame="hsides" rules="groups"&gt;&lt;colgroup span="1"&gt;&lt;col align="left" span="1"/&gt;&lt;col align="char" char="." span="1"/&gt;&lt;col align="char" char="." span="1"/&gt;&lt;col align="char" char="." span="1"/&gt;&lt;col align="char" char="." span="1"/&gt;&lt;col align="center" span="1"/&gt;&lt;/colgroup&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;Haplotype&lt;xref ref-type="table-fn" rid="T3FN1"&gt;*&lt;/xref&gt;&lt;/th&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;Controls (N=694)&lt;/th&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;SSc (N=1050)&lt;/th&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;chi&lt;sup&gt;2&lt;/sup&gt;&lt;/th&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;p&lt;sub&gt;U&lt;/sub&gt;&lt;/th&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;Effect direction&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;OMNIBUS&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;164.3&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;&amp;lt;0.0001&lt;/td&gt;&lt;td align="left" rowspan="1" colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;C-G-A-A-C&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.6%&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;4.9%&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;52.6&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;&amp;lt;0.0001&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;Risk&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;C-G-A-G-C&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;43.4%&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;35.1%&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;25.3&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;&amp;lt;0.0001&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;Protective&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;G-G-C-G-C&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.4%&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;1.7%&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;12.1&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.0006&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;Risk&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;G-G-C-G-T&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.0%&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;1.4%&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;20.6&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;&amp;lt;0.0001&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;Risk&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;G-T-C-G-C&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.6%&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;3.9%&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;37.6&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;&amp;lt;0.0001&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;Risk&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Others&lt;xref ref-type="table-fn" rid="T3FN2"&gt; &lt;/xref&gt;&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;55.0%&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;53.0%&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"/&gt;&lt;td align="char" char="." rowspan="1" colspan="1"/&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;Neutral&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; </infon><infon key="id">T3</infon><infon key="type">table</infon><offset>13041</offset><text>Haplotype* Controls (N=694) SSc (N=1050) chi2 pU Effect direction   OMNIBUS NA NA 164.3 &lt;0.0001    C-G-A-A-C 0.6% 4.9% 52.6 &lt;0.0001 Risk   C-G-A-G-C 43.4% 35.1% 25.3 &lt;0.0001 Protective   G-G-C-G-C 0.4% 1.7% 12.1 0.0006 Risk   G-G-C-G-T 0.0% 1.4% 20.6 &lt;0.0001 Risk   G-T-C-G-C 0.6% 3.9% 37.6 &lt;0.0001 Risk   Others  55.0% 53.0%   Neutral   </text><annotation id="26330"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="13069" length="3" /><text>SSc</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="type">table_footnote</infon><offset>13381</offset><text>The order of the SNPs is rs1234314-rs2205960-rs844644-rs844648-rs844665.</text><annotation id="26331"><infon key="identifier">tmVar:rs1234314;VariantGroup:10;OriginalGene:22164;CorrespondingGene:7292;RS#:1234314;CorrespondingSpecies:10090</infon><infon key="type">SNP</infon><location offset="13406" length="9" /><text>rs1234314</text></annotation><annotation id="26332"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="13416" length="9" /><text>rs2205960</text></annotation><annotation id="26333"><infon key="identifier">tmVar:rs844648;VariantGroup:11;CorrespondingGene:100506023;RS#:844648;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="13435" length="8" /><text>rs844648</text></annotation><annotation id="26334"><infon key="identifier">tmVar:rs844644;VariantGroup:8;CorrespondingGene:100506023;RS#:844644;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="13426" length="8" /><text>rs844644</text></annotation><annotation id="26335"><infon key="identifier">tmVar:rs844665;VariantGroup:7;CorrespondingGene:100506023;RS#:844665;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="13444" length="8" /><text>rs844665</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="type">table_footnote</infon><offset>13462</offset><text>Includes 23 other haplotypes.</text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="type">table_footnote</infon><offset>13492</offset><text>NA, not applicable; pU, uncorrected chi2 p values; SSc, systemic sclerosis; SNP, single nucleotide polymorphism.</text><annotation id="26336"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="13548" length="18" /><text>systemic sclerosis</text></annotation><annotation id="26337"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="13543" length="3" /><text>SSc</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>13605</offset><text>TNFSF4 polymorphisms and association with subsets of SSc</text><annotation id="26338"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="13605" length="6" /><text>TNFSF4</text></annotation><annotation id="26339"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="13658" length="3" /><text>SSc</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>13662</offset><text>SSc is a clinically heterogeneous disease that is divided into two main clinical subsets based on the extent of cutaneous involvement: limited (lSSc) and diffuse (dSSc). Furthermore, the presence of SSc-associated autoantibodies such as ACA, ATA and ARA is associated with distinct clinical subsets characterised by extent of cutaneous involvement and pattern of organ involvement. Several studies have recently shown that certain genetic polymorphisms may have stronger associations with particular phenotypic subsets. Therefore, we compared the frequency of TNFSF4 SNPs within the clinical and autoantibody subsets of patients with SSc (table 4).</text><annotation id="26340"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="14222" length="6" /><text>TNFSF4</text></annotation><annotation id="26341"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="14282" length="8" /><text>patients</text></annotation><annotation id="26342"><infon key="identifier">MESH:C564676</infon><infon key="type">Disease</infon><location offset="13988" length="21" /><text>cutaneous involvement</text></annotation><annotation id="26343"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="13662" length="3" /><text>SSc</text></annotation><annotation id="26344"><infon key="identifier">MESH:C564676</infon><infon key="type">Disease</infon><location offset="13774" length="21" /><text>cutaneous involvement</text></annotation><annotation id="26345"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="14296" length="3" /><text>SSc</text></annotation><annotation id="26346"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="13861" length="3" /><text>SSc</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="type">table_caption</infon><offset>14311</offset><text>Distribution of the tumour necrosis factor ligand superfamily member 4 gene (TNFSF4) SNP alleles in North American Caucasian patients with SSc and normal controls*</text><annotation id="26347"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="14388" length="6" /><text>TNFSF4</text></annotation><annotation id="26348"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="14450" length="3" /><text>SSc</text></annotation><annotation id="26349"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="14436" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T4.xml</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt; &lt;table frame="hsides" rules="groups"&gt;&lt;colgroup span="1"&gt;&lt;col align="left" span="1"/&gt;&lt;col align="right" span="1"/&gt;&lt;col align="char" char="." span="1"/&gt;&lt;col align="char" char="." span="1"/&gt;&lt;col align="char" char="." span="1"/&gt;&lt;col align="char" char="." span="1"/&gt;&lt;col align="char" char="(" span="1"/&gt;&lt;/colgroup&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align="left" rowspan="1" colspan="1"/&gt;&lt;th align="left" colspan="6" rowspan="1"&gt;Allelic comparison&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th align="left" rowspan="1" colspan="1"/&gt;&lt;th align="left" rowspan="1" colspan="1"/&gt;&lt;th align="center" colspan="2" rowspan="1"&gt;%&lt;/th&gt;&lt;th align="left" rowspan="1" colspan="1"/&gt;&lt;th align="left" rowspan="1" colspan="1"/&gt;&lt;th align="left" rowspan="1" colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th align="left" rowspan="1" colspan="1"/&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;N&lt;/th&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;C&lt;/th&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;G&lt;/th&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;p&lt;sub&gt;U&lt;/sub&gt;&lt;/th&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;p&lt;sub&gt;FDR&lt;/sub&gt;&lt;/th&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;OR (95% CI)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left" colspan="7" rowspan="1"&gt;rs1234314&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Controls&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;1362&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;58.7&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;41.3&lt;/td&gt;&lt;td align="left" rowspan="1" colspan="1"/&gt;&lt;td align="left" rowspan="1" colspan="1"/&gt;&lt;td align="left" rowspan="1" colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Patients with systemic sclerosis&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;2086&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;54.2&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;45.8&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.01&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.019&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.20 (1.04 to 1.4)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Limited systemic sclerosis&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;1202&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;53.4&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;46.6&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.009&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.026&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.24 (1.1 to 1.5)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Diffuse systemic sclerosis&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;774&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;54.3&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;45.7&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.048&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.048&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.20 (1.1 to 1.4)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" colspan="7" rowspan="1"&gt; Antibodies&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Anti-centromere&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;586&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;51.7&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;48.3&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.005&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.018&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.33 (1.1 to 1.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Anti-topoisomerase I&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;344&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;52.0&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;48.0&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.026&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.052&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.31 (1.02 to 1.7)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Anti-RNA polymerase III&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;380&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;54.7&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;45.3&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.17&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.23&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.17 (0.9 to 1.5)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" colspan="7" rowspan="1"&gt;rs2205960&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Controls&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;1378&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;78.8&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;21.2&lt;/td&gt;&lt;td align="left" rowspan="1" colspan="1"/&gt;&lt;td align="left" rowspan="1" colspan="1"/&gt;&lt;td align="left" rowspan="1" colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Patients with systemic sclerosis&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;2058&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;75.0&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;25.0&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.01&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.019&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.24(1.1 to 1.5)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Limited systemic sclerosis&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;1184&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;74.7&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;25.3&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.013&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.026&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.26 (1.1 to 1.5)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Diffuse systemic sclerosis&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;764&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;74.9&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;25.1&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.037&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.048&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.25 (1.01 to 1.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" colspan="7" rowspan="1"&gt; Antibodies&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Anti-centromere&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;586&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;74.4&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;25.6&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.032&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.056&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.28 (1.01 to 1.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Anti-topoisomerase I&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;342&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;72.5&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;27.5&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.012&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.048&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.41 (1.1 to 1.9)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Anti-RNA polymerase III&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;372&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;74.2&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;25.8&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.057&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.11&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.29 (0.98 to 1.7)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" colspan="7" rowspan="1"&gt;rs844644&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Controls&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;1378&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;49.1&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;50.9&lt;/td&gt;&lt;td align="left" rowspan="1" colspan="1"/&gt;&lt;td align="left" rowspan="1" colspan="1"/&gt;&lt;td align="left" rowspan="1" colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Patients with systemic sclerosis&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;2090&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;44.8&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;55.2&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.01&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.019&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;0.84 (0.7 to 0.97)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Limited systemic sclerosis&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;1206&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;45.1&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;54.9&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.045&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.06&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;0.85 (0.7 to 1.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Diffuse systemic sclerosis&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;774&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;43.8&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;56.2&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.019&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.038&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;0.81 (0.7 to 0.97)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" colspan="7" rowspan="1"&gt; Antibodies&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Anti-centromere&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;590&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;44.1&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;55.9&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.042&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.056&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;0.82 (0.7 to 1.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Anti-topoisomerase I&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;346&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;43.1&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;56.9&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.046&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.055&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;0.79 (0.6 to 1.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Anti-RNA polymerase III&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;380&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;45.8&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;54.2&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.26&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.26&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;0.88 (0.7 to 1.1)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" colspan="7" rowspan="1"&gt;rs844648&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Controls&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;1384&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;41.4&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;58.6&lt;/td&gt;&lt;td align="left" rowspan="1" colspan="1"/&gt;&lt;td align="left" rowspan="1" colspan="1"/&gt;&lt;td align="left" rowspan="1" colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Patients with systemic sclerosis&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;2094&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;45.1&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;54.9&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.03&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.032&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.16 (1.01 to 1.3)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Limited systemic sclerosis&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;1206&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;44.0&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;56.0&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.18&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.18&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.11 (0.95 to 1.3)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Diffuse systemic sclerosis&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;778&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;48.2&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;51.8&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.002&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.008&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.32 (1.1 to 1.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" colspan="7" rowspan="1"&gt; Antibodies&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Anti-centromere&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;592&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;42.6&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;57.4&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.63&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.63&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.05 (0.9 to 1.3)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Anti-topoisomerase I&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;346&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;47.1&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;52.9&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.055&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.055&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.26 (0.99 to 1.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Anti-RNA polymerase III&lt;/td&gt;&lt;td align="right" rowspan="1" colspan="1"&gt;382&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;49.7&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;50.3&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.004&lt;/td&gt;&lt;td align="char" char="." rowspan="1" colspan="1"&gt;0.014&lt;/td&gt;&lt;td align="char" char="(" rowspan="1" colspan="1"&gt;1.40 (1.1 to 1.8)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; </infon><infon key="id">T4</infon><infon key="type">table</infon><offset>14475</offset><text> Allelic comparison     %       N C G pU pFDR OR (95% CI)   rs1234314    Controls 1362 58.7 41.3       Patients with systemic sclerosis 2086 54.2 45.8 0.01 0.019 1.20 (1.04 to 1.4)    Limited systemic sclerosis 1202 53.4 46.6 0.009 0.026 1.24 (1.1 to 1.5)    Diffuse systemic sclerosis 774 54.3 45.7 0.048 0.048 1.20 (1.1 to 1.4)    Antibodies    Anti-centromere 586 51.7 48.3 0.005 0.018 1.33 (1.1 to 1.6)    Anti-topoisomerase I 344 52.0 48.0 0.026 0.052 1.31 (1.02 to 1.7)    Anti-RNA polymerase III 380 54.7 45.3 0.17 0.23 1.17 (0.9 to 1.5)   rs2205960    Controls 1378 78.8 21.2       Patients with systemic sclerosis 2058 75.0 25.0 0.01 0.019 1.24(1.1 to 1.5)    Limited systemic sclerosis 1184 74.7 25.3 0.013 0.026 1.26 (1.1 to 1.5)    Diffuse systemic sclerosis 764 74.9 25.1 0.037 0.048 1.25 (1.01 to 1.6)    Antibodies    Anti-centromere 586 74.4 25.6 0.032 0.056 1.28 (1.01 to 1.6)    Anti-topoisomerase I 342 72.5 27.5 0.012 0.048 1.41 (1.1 to 1.9)    Anti-RNA polymerase III 372 74.2 25.8 0.057 0.11 1.29 (0.98 to 1.7)   rs844644    Controls 1378 49.1 50.9       Patients with systemic sclerosis 2090 44.8 55.2 0.01 0.019 0.84 (0.7 to 0.97)    Limited systemic sclerosis 1206 45.1 54.9 0.045 0.06 0.85 (0.7 to 1.0)    Diffuse systemic sclerosis 774 43.8 56.2 0.019 0.038 0.81 (0.7 to 0.97)    Antibodies    Anti-centromere 590 44.1 55.9 0.042 0.056 0.82 (0.7 to 1.0)    Anti-topoisomerase I 346 43.1 56.9 0.046 0.055 0.79 (0.6 to 1.0)    Anti-RNA polymerase III 380 45.8 54.2 0.26 0.26 0.88 (0.7 to 1.1)   rs844648    Controls 1384 41.4 58.6       Patients with systemic sclerosis 2094 45.1 54.9 0.03 0.032 1.16 (1.01 to 1.3)    Limited systemic sclerosis 1206 44.0 56.0 0.18 0.18 1.11 (0.95 to 1.3)    Diffuse systemic sclerosis 778 48.2 51.8 0.002 0.008 1.32 (1.1 to 1.6)    Antibodies    Anti-centromere 592 42.6 57.4 0.63 0.63 1.05 (0.9 to 1.3)    Anti-topoisomerase I 346 47.1 52.9 0.055 0.055 1.26 (0.99 to 1.6)    Anti-RNA polymerase III 382 49.7 50.3 0.004 0.014 1.40 (1.1 to 1.8)   </text><annotation id="26350"><infon key="identifier">tmVar:rs1234314;VariantGroup:10;OriginalGene:22164;CorrespondingGene:7292;RS#:1234314;CorrespondingSpecies:10090</infon><infon key="type">SNP</infon><location offset="14535" length="9" /><text>rs1234314</text></annotation><annotation id="26351"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="14578" length="8" /><text>Patients</text></annotation><annotation id="26352"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="15065" length="8" /><text>Patients</text></annotation><annotation id="26353"><infon key="identifier">tmVar:rs844648;VariantGroup:11;CorrespondingGene:100506023;RS#:844648;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="15995" length="8" /><text>rs844648</text></annotation><annotation id="26354"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="15079" length="18" /><text>systemic sclerosis</text></annotation><annotation id="26355"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="15633" length="26" /><text>Limited systemic sclerosis</text></annotation><annotation id="26356"><infon key="identifier">MESH:D045743</infon><infon key="type">Disease</infon><location offset="15707" length="26" /><text>Diffuse systemic sclerosis</text></annotation><annotation id="26357"><infon key="identifier">MESH:D045743</infon><infon key="type">Disease</infon><location offset="14734" length="26" /><text>Diffuse systemic sclerosis</text></annotation><annotation id="26358"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="16118" length="26" /><text>Limited systemic sclerosis</text></annotation><annotation id="26359"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="14592" length="18" /><text>systemic sclerosis</text></annotation><annotation id="26360"><infon key="identifier">MESH:D045743</infon><infon key="type">Disease</infon><location offset="16192" length="26" /><text>Diffuse systemic sclerosis</text></annotation><annotation id="26361"><infon key="identifier">MESH:D045743</infon><infon key="type">Disease</infon><location offset="15219" length="26" /><text>Diffuse systemic sclerosis</text></annotation><annotation id="26362"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="16051" length="18" /><text>systemic sclerosis</text></annotation><annotation id="26363"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="15566" length="18" /><text>systemic sclerosis</text></annotation><annotation id="26364"><infon key="identifier">tmVar:rs844644;VariantGroup:8;CorrespondingGene:100506023;RS#:844644;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="15510" length="8" /><text>rs844644</text></annotation><annotation id="26365"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="15552" length="8" /><text>Patients</text></annotation><annotation id="26366"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="16037" length="8" /><text>Patients</text></annotation><annotation id="26367"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="15144" length="26" /><text>Limited systemic sclerosis</text></annotation><annotation id="26368"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="14659" length="26" /><text>Limited systemic sclerosis</text></annotation><annotation id="26369"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="15022" length="9" /><text>rs2205960</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="type">table_footnote</infon><offset>16545</offset><text>Controls are used as reference for all comparisons.</text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="type">table_footnote</infon><offset>16597</offset><text>pFDR, corrected p values using Benjamini and Hochberg false discovery rate method; pU, raw chi2 p values; SSc, systemic sclerosis; SNP, single nucleotide polymorphism.</text><annotation id="26370"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="16708" length="18" /><text>systemic sclerosis</text></annotation><annotation id="26371"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="16703" length="3" /><text>SSc</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>16765</offset><text>The minor alleles at TNFSF4 SNPs rs1234314 and rs2205960 were more common in lSSc compared to controls. No differences were observed with rs844644 and rs844648 between lSSc and controls. Compared to controls, the patients with dSSc had an increased frequency of the minor alleles at TNFSF4 SNPs rs1234314, rs2205960 and rs844648 and decreased frequency of the minor allele at rs844644. Comparison of patients with and without pulmonary fibrosis or pulmonary hypertension did not reveal any differences in the frequency of the SNPs in the TNFSF4 gene region.</text><annotation id="26372"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="16786" length="6" /><text>TNFSF4</text></annotation><annotation id="26373"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="17048" length="6" /><text>TNFSF4</text></annotation><annotation id="26374"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="17303" length="6" /><text>TNFSF4</text></annotation><annotation id="26375"><infon key="identifier">tmVar:rs844648;VariantGroup:11;CorrespondingGene:100506023;RS#:844648;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="16916" length="8" /><text>rs844648</text></annotation><annotation id="26376"><infon key="type">Disease</infon><location offset="16992" length="4" /><text>dSSc</text></annotation><annotation id="26377"><infon key="identifier">MESH:D011658</infon><infon key="type">Disease</infon><location offset="17191" length="18" /><text>pulmonary fibrosis</text></annotation><annotation id="26378"><infon key="identifier">tmVar:rs1234314;VariantGroup:10;OriginalGene:22164;CorrespondingGene:7292;RS#:1234314;CorrespondingSpecies:10090</infon><infon key="type">SNP</infon><location offset="16798" length="9" /><text>rs1234314</text></annotation><annotation id="26379"><infon key="identifier">MESH:D006976</infon><infon key="type">Disease</infon><location offset="17213" length="22" /><text>pulmonary hypertension</text></annotation><annotation id="26380"><infon key="type">Disease</infon><location offset="16933" length="4" /><text>lSSc</text></annotation><annotation id="26381"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="16978" length="8" /><text>patients</text></annotation><annotation id="26382"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="16812" length="9" /><text>rs2205960</text></annotation><annotation id="26383"><infon key="identifier">tmVar:rs844648;VariantGroup:11;CorrespondingGene:100506023;RS#:844648;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="17085" length="8" /><text>rs844648</text></annotation><annotation id="26384"><infon key="identifier">tmVar:rs844644;VariantGroup:8;CorrespondingGene:100506023;RS#:844644;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="16903" length="8" /><text>rs844644</text></annotation><annotation id="26385"><infon key="identifier">tmVar:rs844644;VariantGroup:8;CorrespondingGene:100506023;RS#:844644;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="17141" length="8" /><text>rs844644</text></annotation><annotation id="26386"><infon key="type">Disease</infon><location offset="16842" length="4" /><text>lSSc</text></annotation><annotation id="26387"><infon key="identifier">tmVar:rs1234314;VariantGroup:10;OriginalGene:22164;CorrespondingGene:7292;RS#:1234314;CorrespondingSpecies:10090</infon><infon key="type">SNP</infon><location offset="17060" length="9" /><text>rs1234314</text></annotation><annotation id="26388"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="17165" length="8" /><text>patients</text></annotation><annotation id="26389"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="17071" length="9" /><text>rs2205960</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>17323</offset><text>Using the SSc-associated autoantibodies to subset patients with SSc, a significant association was observed with rs1234214 and ACA-positive (OR 1.3, 95% CI 1.1 to 1.6) and ATA-positive patients with SSc (OR 1.3, 95% CI 1.02 to 1.7) compared to controls. The minor allele at rs2205960 was more frequent in ATA-positive SSc compared to controls (OR 1.4, 95% CI 1.1 to 1.9). Interestingly, only rs844648 was noted to be associated with ARA-positive SSc compared to controls (OR 1.4, 95% CI 1.1 to 1.8). No significant differences were noted in the SSc-associated autoantibody subsets of SSc compared to controls at rs844644.</text><annotation id="26390"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="17495" length="3" /><text>ATA</text></annotation><annotation id="26391"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="17597" length="9" /><text>rs2205960</text></annotation><annotation id="26392"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="17333" length="3" /><text>SSc</text></annotation><annotation id="26393"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="17868" length="3" /><text>SSc</text></annotation><annotation id="26394"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="17769" length="3" /><text>SSc</text></annotation><annotation id="26395"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="17508" length="8" /><text>patients</text></annotation><annotation id="26396"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="17373" length="8" /><text>patients</text></annotation><annotation id="26397"><infon key="identifier">tmVar:rs1234214;VariantGroup:9;CorrespondingGene:5728;RS#:1234214;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="17436" length="9" /><text>rs1234214</text></annotation><annotation id="26398"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="17628" length="3" /><text>ATA</text></annotation><annotation id="26399"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="17387" length="3" /><text>SSc</text></annotation><annotation id="26400"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="17522" length="3" /><text>SSc</text></annotation><annotation id="26401"><infon key="identifier">tmVar:rs844648;VariantGroup:11;CorrespondingGene:100506023;RS#:844648;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="17715" length="8" /><text>rs844648</text></annotation><annotation id="26402"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="17907" length="3" /><text>SSc</text></annotation><annotation id="26403"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="17641" length="3" /><text>SSc</text></annotation><annotation id="26404"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="17756" length="3" /><text>ARA</text></annotation><annotation id="26405"><infon key="identifier">tmVar:rs844644;VariantGroup:8;CorrespondingGene:100506023;RS#:844644;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="17935" length="8" /><text>rs844644</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>17945</offset><text>Additional analyses were performed using logistic regression with gender added to the model (figure 2). The strongest associations were observed with rs2205960, where the minor allele was observed with increased frequency in lSSc and dSSc as well as the autoantibody subsets. The minor allele at rs844644 was protective in all groups except for the patients who were ARA positive. With regards to rs1234314, the associations remained in lSSc, ACA and ATA groups. However, the association of rs1234314 was no longer observed after controlling for gender in the logistic regression analyses. Lastly, with regards to rs844648, logistic regression confirmed the association with dSSc and ARA. Together these data suggest that different polymorphisms in the TNFSF4 gene region are associated with susceptibility to the distinct autoantibody and skin subsets in SSc.</text><annotation id="26406"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="18698" length="6" /><text>TNFSF4</text></annotation><annotation id="26407"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="18629" length="3" /><text>ARA</text></annotation><annotation id="26408"><infon key="identifier">tmVar:rs1234314;VariantGroup:10;OriginalGene:22164;CorrespondingGene:7292;RS#:1234314;CorrespondingSpecies:10090</infon><infon key="type">SNP</infon><location offset="18342" length="9" /><text>rs1234314</text></annotation><annotation id="26409"><infon key="identifier">tmVar:rs844644;VariantGroup:8;CorrespondingGene:100506023;RS#:844644;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="18241" length="8" /><text>rs844644</text></annotation><annotation id="26410"><infon key="identifier">tmVar:rs1234314;VariantGroup:10;OriginalGene:22164;CorrespondingGene:7292;RS#:1234314;CorrespondingSpecies:10090</infon><infon key="type">SNP</infon><location offset="18436" length="9" /><text>rs1234314</text></annotation><annotation id="26411"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="18801" length="3" /><text>SSc</text></annotation><annotation id="26412"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="18095" length="9" /><text>rs2205960</text></annotation><annotation id="26413"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="18294" length="8" /><text>patients</text></annotation><annotation id="26414"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="18312" length="3" /><text>ARA</text></annotation><annotation id="26415"><infon key="identifier">tmVar:rs844648;VariantGroup:11;CorrespondingGene:100506023;RS#:844648;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="18559" length="8" /><text>rs844648</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>18806</offset><text>CART analysis for SNP interaction in the TNFSF4 gene region</text><annotation id="26416"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="18847" length="6" /><text>TNFSF4</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>18866</offset><text>To identify the SNP(s) in TNFSF4 that play a more prominent role in SSc susceptibility, CART analysis was performed. Accordingly, the five TNFSF4 polymorphisms and gender were entered as variables in the CART model. CART analysis interactively segregates participants into two subgroups using the most powerful variable classifier for SSc.</text><annotation id="26417"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="18892" length="6" /><text>TNFSF4</text></annotation><annotation id="26418"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="19005" length="6" /><text>TNFSF4</text></annotation><annotation id="26419"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="19201" length="3" /><text>SSc</text></annotation><annotation id="26420"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="18934" length="3" /><text>SSc</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>19206</offset><text>Figure 3 depicts female gender as the first split. In women, the 'TT/GT' genotype of the TNFSF4 variant (rs2205960) increased risk for SSc as compared to the 'GG' wild-type genotype (OR = 1.51, 95% CI 1.2 to 1.9) consistent with a dominant model. The individuals with wild-type genotype 'GG' at rs2205960 were subsequently further split by the TNFSF4 variant (rs855648) into two subgroups: the 'AA' genotype of the TNFSF4 variant increased risk for SSc as compared to the 'AG/GG' genotypes (OR=2.55, 95% CI 1.3 to 5.3). Therefore, this analysis uncovered a potential interaction between the rs2205960 and rs855648 SNPs in the TNFSF4 gene region among women patients with SSc. This interaction between the two TNFSF4 variants, rs2205960 and rs855648, was further tested and confirmed by an interaction model in logistic regression analysis (p=0.0004).</text><annotation id="26421"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="19295" length="6" /><text>TNFSF4</text></annotation><annotation id="26422"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="19550" length="6" /><text>TNFSF4</text></annotation><annotation id="26423"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="19621" length="6" /><text>TNFSF4</text></annotation><annotation id="26424"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="19832" length="6" /><text>TNFSF4</text></annotation><annotation id="26425"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="19915" length="6" /><text>TNFSF4</text></annotation><annotation id="26426"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="19341" length="3" /><text>SSc</text></annotation><annotation id="26427"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="19260" length="5" /><text>women</text></annotation><annotation id="26428"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="19863" length="8" /><text>patients</text></annotation><annotation id="26429"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="19797" length="9" /><text>rs2205960</text></annotation><annotation id="26430"><infon key="identifier">tmVar:rs855648;VariantGroup:13;RS#:855648</infon><infon key="type">SNP</infon><location offset="19566" length="8" /><text>rs855648</text></annotation><annotation id="26431"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="19311" length="9" /><text>rs2205960</text></annotation><annotation id="26432"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="19655" length="3" /><text>SSc</text></annotation><annotation id="26433"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="19877" length="3" /><text>SSc</text></annotation><annotation id="26434"><infon key="identifier">tmVar:rs855648;VariantGroup:13;RS#:855648</infon><infon key="type">SNP</infon><location offset="19946" length="8" /><text>rs855648</text></annotation><annotation id="26435"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="19857" length="5" /><text>women</text></annotation><annotation id="26436"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="19932" length="9" /><text>rs2205960</text></annotation><annotation id="26437"><infon key="identifier">tmVar:rs855648;VariantGroup:13;RS#:855648</infon><infon key="type">SNP</infon><location offset="19811" length="8" /><text>rs855648</text></annotation><annotation id="26438"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="19501" length="9" /><text>rs2205960</text></annotation></passage><passage><infon key="section_type">FIG</infon><infon key="file">ard-69-03-0550-fig3.jpg</infon><infon key="id">F3</infon><infon key="type">fig_caption</infon><offset>20077</offset><text>Cartesian and regression tree analysis (CART) showing an interaction between the tumour necrosis factor ligand superfamily member 4 gene (TNFSF4) single nucleotide polymorphisms (SNPs) rs2205960 and rs944648 in systemic sclerosis (SSc). Red test result denotes SSc susceptibility factors.</text><annotation id="26439"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="20215" length="6" /><text>TNFSF4</text></annotation><annotation id="26440"><infon key="identifier">tmVar:rs944648;VariantGroup:2;CorrespondingGene:158038;RS#:944648;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="20276" length="8" /><text>rs944648</text></annotation><annotation id="26441"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="20308" length="3" /><text>SSc</text></annotation><annotation id="26442"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="20338" length="3" /><text>SSc</text></annotation><annotation id="26443"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="20262" length="9" /><text>rs2205960</text></annotation><annotation id="26444"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="20288" length="18" /><text>systemic sclerosis</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>20366</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>20377</offset><text>The current report is the first demonstration of an association of polymorphisms in the TNFSF4 gene region with susceptibility to SSc in North American Caucasians. These associations were similar when comparing lSSc and dSSc with controls. We also identified particular SNPs in the TNFSF4 gene region that are associated with the SSc-associated autoantibody subsets of SSc. Lastly, the exploratory method of analysis, CART, demonstrated a potential interaction between the TNFSF4 SNPs rs2205960 and rs855648 among Caucasian women patients with SSc that was confirmed by logistic regression analysis.</text><annotation id="26445"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="20465" length="6" /><text>TNFSF4</text></annotation><annotation id="26446"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="20659" length="6" /><text>TNFSF4</text></annotation><annotation id="26447"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="20850" length="6" /><text>TNFSF4</text></annotation><annotation id="26448"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="20907" length="8" /><text>patients</text></annotation><annotation id="26449"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="20746" length="3" /><text>SSc</text></annotation><annotation id="26450"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="20507" length="3" /><text>SSc</text></annotation><annotation id="26451"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="20707" length="3" /><text>SSc</text></annotation><annotation id="26452"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="20901" length="5" /><text>women</text></annotation><annotation id="26453"><infon key="identifier">tmVar:rs2205960;VariantGroup:14;RS#:2205960</infon><infon key="type">SNP</infon><location offset="20862" length="9" /><text>rs2205960</text></annotation><annotation id="26454"><infon key="identifier">tmVar:rs855648;VariantGroup:13;RS#:855648</infon><infon key="type">SNP</infon><location offset="20876" length="8" /><text>rs855648</text></annotation><annotation id="26455"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="20921" length="3" /><text>SSc</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>20977</offset><text>TNFSF4 encodes for the protein OX40 ligand (OX40L). OX40L is expressed on dendritic cells, macrophages, B cells, T cells, natural killer (NK) cells as well as non-immune cells such as endothelial cells and smooth muscle cells. It is the ligand for the OX40 which is expressed on CD4+ and CD8+ T cells, where it provides a costimulatory signal resulting in T cell proliferation, survival and cytokine production. Several studies have suggested that OX40-OX40L interaction may preferentially promote T helper (Th)2 cytokines and may be a negative regulatory signal for interleukin (IL)17 production. More recently it has been suggested that OX40-OX40L interactions inhibit the formation of Foxp3+ regulatory T cells. In addition to T cell effects, OX40-OX40L interactions also have been reported to be critical in differentiation of B cells and antibody production. Lastly, it has been reported that plasmacytoid dendritic cells may regulate T helper responses through a balance of OX40L expression and type I interferon expression such that OX40L alone induces a Th2 response and OX40L with type I interferon may have a Th1 inducing effect. Together these studies suggest an important role for OX40-OX40L interactions in critical immunoregulatory checkpoints that are likely involved in the development of autoimmunity. Accordingly, OX40L transgenic mice on the C57/BL6 background develop organ specific inflammation and targeted strategies to block OX40-OX40L interactions have prevented the development of diabetes in the non-obese diabetic mouse and experimental autoimmune encephalomyelitis, a model for multiple sclerosis. It is likely that these pathways and OX40L-dependent immune alterations are important in the development of SSc. Indeed serum levels of OX40 have been reported to be elevated in patients with SSc, suggesting that the OX40-OX40L pathway may be involved in SSc. However, specifically how the OX40L polymorphisms lead to the development of SSc is unknown.</text><annotation id="26456"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="20977" length="6" /><text>TNFSF4</text></annotation><annotation id="26457"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="21008" length="11" /><text>OX40 ligand</text></annotation><annotation id="26458"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="21021" length="5" /><text>OX40L</text></annotation><annotation id="26459"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="21029" length="5" /><text>OX40L</text></annotation><annotation id="26460"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="21229" length="4" /><text>OX40</text></annotation><annotation id="26461"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="21256" length="3" /><text>CD4</text></annotation><annotation id="26462"><infon key="identifier">925</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">133777</infon><location offset="21265" length="3" /><text>CD8</text></annotation><annotation id="26463"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="21425" length="4" /><text>OX40</text></annotation><annotation id="26464"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="21430" length="5" /><text>OX40L</text></annotation><annotation id="26465"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="21616" length="4" /><text>OX40</text></annotation><annotation id="26466"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="21621" length="5" /><text>OX40L</text></annotation><annotation id="26467"><infon key="identifier">50943</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8516</infon><location offset="21665" length="5" /><text>Foxp3</text></annotation><annotation id="26468"><infon key="identifier">22163</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="21723" length="4" /><text>OX40</text></annotation><annotation id="26469"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="21728" length="5" /><text>OX40L</text></annotation><annotation id="26470"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="21957" length="5" /><text>OX40L</text></annotation><annotation id="26471"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="22017" length="5" /><text>OX40L</text></annotation><annotation id="26472"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="22056" length="5" /><text>OX40L</text></annotation><annotation id="26473"><infon key="identifier">22163</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="22170" length="4" /><text>OX40</text></annotation><annotation id="26474"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="22175" length="5" /><text>OX40L</text></annotation><annotation id="26475"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="22309" length="5" /><text>OX40L</text></annotation><annotation id="26476"><infon key="identifier">22163</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="22426" length="4" /><text>OX40</text></annotation><annotation id="26477"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="22431" length="5" /><text>OX40L</text></annotation><annotation id="26478"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="22641" length="5" /><text>OX40L</text></annotation><annotation id="26479"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="22740" length="4" /><text>OX40</text></annotation><annotation id="26480"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="22821" length="4" /><text>OX40</text></annotation><annotation id="26481"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="22826" length="5" /><text>OX40L</text></annotation><annotation id="26482"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="22894" length="5" /><text>OX40L</text></annotation><annotation id="26483"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="22519" length="5" /><text>mouse</text></annotation><annotation id="26484"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="22510" length="8" /><text>diabetic</text></annotation><annotation id="26485"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="22484" length="8" /><text>diabetes</text></annotation><annotation id="26486"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="22941" length="3" /><text>SSc</text></annotation><annotation id="26487"><infon key="identifier">MESH:D009103</infon><infon key="type">Disease</infon><location offset="22584" length="18" /><text>multiple sclerosis</text></annotation><annotation id="26488"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="22326" length="4" /><text>mice</text></annotation><annotation id="26489"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="22712" length="3" /><text>SSc</text></annotation><annotation id="26490"><infon key="identifier">MESH:D001327</infon><infon key="type">Disease</infon><location offset="22282" length="12" /><text>autoimmunity</text></annotation><annotation id="26491"><infon key="identifier">MESH:D004681</infon><infon key="type">Disease</infon><location offset="22529" length="41" /><text>experimental autoimmune encephalomyelitis</text></annotation><annotation id="26492"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="22796" length="3" /><text>SSc</text></annotation><annotation id="26493"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="22782" length="8" /><text>patients</text></annotation><annotation id="26494"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="22380" length="12" /><text>inflammation</text></annotation><annotation id="26495"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="22504" length="5" /><text>obese</text></annotation><annotation id="26496"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="22859" length="3" /><text>SSc</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>22969</offset><text>The current report adds TNFSF4 to the list of genes that are associated with SSc susceptibility which includes major histocompatibility complex (MHC) class II, PTPN22, AIF1, IRF5, STAT4 and FAS. Furthermore, given the association of TNFSF4 with SLE as well as SSc, it is likely that TNFSF4 is a gene that confers risk to multiple autoimmune diseases. Why individual patients will develop a specific autoimmune disease such as SLE, RA, or SSc remains unknown. Functional studies of the polymorphisms in these genes as well as studies of gene-gene and gene-environment interactions are necessary to better understand how the genetic associations lead to specific autoimmune diseases.</text><annotation id="26497"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="22993" length="6" /><text>TNFSF4</text></annotation><annotation id="26498"><infon key="identifier">26191</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7498</infon><location offset="23129" length="6" /><text>PTPN22</text></annotation><annotation id="26499"><infon key="identifier">199</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1226</infon><location offset="23137" length="4" /><text>AIF1</text></annotation><annotation id="26500"><infon key="identifier">3663</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8088</infon><location offset="23143" length="4" /><text>IRF5</text></annotation><annotation id="26501"><infon key="identifier">6775</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20679</infon><location offset="23149" length="5" /><text>STAT4</text></annotation><annotation id="26502"><infon key="identifier">355</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">27</infon><location offset="23159" length="3" /><text>FAS</text></annotation><annotation id="26503"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="23202" length="6" /><text>TNFSF4</text></annotation><annotation id="26504"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="23252" length="6" /><text>TNFSF4</text></annotation><annotation id="26505"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="23395" length="3" /><text>SLE</text></annotation><annotation id="26506"><infon key="identifier">MESH:D001327</infon><infon key="type">Disease</infon><location offset="23299" length="19" /><text>autoimmune diseases</text></annotation><annotation id="26507"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="23229" length="3" /><text>SSc</text></annotation><annotation id="26508"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="23335" length="8" /><text>patients</text></annotation><annotation id="26509"><infon key="identifier">MESH:D001327</infon><infon key="type">Disease</infon><location offset="23368" length="18" /><text>autoimmune disease</text></annotation><annotation id="26510"><infon key="identifier">MESH:D001327</infon><infon key="type">Disease</infon><location offset="23630" length="19" /><text>autoimmune diseases</text></annotation><annotation id="26511"><infon key="identifier">MESH:D001172</infon><infon key="type">Disease</infon><location offset="23400" length="2" /><text>RA</text></annotation><annotation id="26512"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="23046" length="3" /><text>SSc</text></annotation><annotation id="26513"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="23407" length="3" /><text>SSc</text></annotation><annotation id="26514"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="23214" length="3" /><text>SLE</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>23655</offset><text>Our study, despite its large size, is limited to the North American Caucasian population. Current efforts are underway to confirm these findings in other populations. However, we believe that the prior association of TNFSF4 with SLE and the emerging concepts of shared autoimmune genes provide some validation of our novel findings in SSc. Furthermore, the odds ratios that we observed in the current study are small, but statistically significant. It is well established that SSc and other autoimmune diseases are complex polygenic diseases and it will be important to investigate for interactions among these candidate genes in the future. Another important limitation to consider when interpreting the findings of the current study is that our data demonstrate an association of a region 5' of the TNFSF4 gene region with SSc susceptibility. These SNPs have been reported to be within the promoter region of TNFSF4 but their specific regulatory role is not known. Higher resolution genotyping or DNA sequencing of this region gene will help to identify the SNPs involved in SSc pathogenesis and also determine the variation in genetic structure of this gene in various populations.</text><annotation id="26515"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="23872" length="6" /><text>TNFSF4</text></annotation><annotation id="26516"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="24456" length="6" /><text>TNFSF4</text></annotation><annotation id="26517"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="24566" length="6" /><text>TNFSF4</text></annotation><annotation id="26518"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="24732" length="3" /><text>SSc</text></annotation><annotation id="26519"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="23990" length="3" /><text>SSc</text></annotation><annotation id="26520"><infon key="identifier">MESH:D001327</infon><infon key="type">Disease</infon><location offset="24146" length="19" /><text>autoimmune diseases</text></annotation><annotation id="26521"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="24480" length="3" /><text>SSc</text></annotation><annotation id="26522"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="24132" length="3" /><text>SSc</text></annotation><annotation id="26523"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="23884" length="3" /><text>SLE</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>24842</offset><text>To summarise, the current report identifies TNFSF4 as a susceptibility gene for the development of SSc. These data further our understanding of the complex immunopathogenesis of SSc and provide additional support for the emerging concept of shared genes in multiple autoimmune diseases.</text><annotation id="26524"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="24886" length="6" /><text>TNFSF4</text></annotation><annotation id="26525"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="25020" length="3" /><text>SSc</text></annotation><annotation id="26526"><infon key="identifier">MESH:D001327</infon><infon key="type">Disease</infon><location offset="25108" length="19" /><text>autoimmune diseases</text></annotation><annotation id="26527"><infon key="identifier">MESH:D012595</infon><infon key="type">Disease</infon><location offset="24941" length="3" /><text>SSc</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">footnote</infon><offset>25129</offset><text>Ethics approval: This study was conducted with the approval of the University of Texas Health Science Center at Houston Medical School IRB (Committee for the Protection of Human Subjects).</text><annotation id="26528"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="25301" length="5" /><text>Human</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">footnote</infon><offset>25318</offset><text>Contributors: All authors contributed to the following criteria for the manuscript authorship conception and design, or analysis and interpretation of data drafting the article or revising it critically for important intellectual content and final approval of the version to be published.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">footnote</infon><offset>25607</offset><text>Provenance and peer review: Not commissioned; externally peer reviewed.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>25679</offset><text>References</text></passage><passage><infon key="volume">77</infon><infon key="name_2">surname:Remmers;given-names:EF</infon><infon key="name_1">surname:Padyukov;given-names:L</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Plenge;given-names:RM</infon><infon key="fpage">1044</infon><infon key="pub-id_pmid">16380915</infon><infon key="year">2005</infon><infon key="source">Am J Hum Genet</infon><infon key="type">ref</infon><infon key="lpage">60</infon><offset>25690</offset><text>Replication of putative candidate-gene associations with rheumatoid arthritis in &gt;4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4</text><annotation id="26529"><infon key="identifier">26191</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7498</infon><location offset="25852" length="6" /><text>PTPN22</text></annotation></passage><passage><infon key="volume">360</infon><infon key="name_2">surname:Nepom;given-names:GT</infon><infon key="name_1">surname:Rich;given-names:SS</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Concannon;given-names:P</infon><infon key="fpage">1646</infon><infon key="pub-id_pmid">19369670</infon><infon key="year">2009</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="lpage">54</infon><offset>25877</offset><text>Genetics of type 1A diabetes</text></passage><passage><infon key="volume">10</infon><infon key="name_2">surname:Langefeld;given-names:CD</infon><infon key="name_1">surname:Kaufman;given-names:KM</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Harley;given-names:IT</infon><infon key="fpage">285</infon><infon key="pub-id_pmid">19337289</infon><infon key="year">2009</infon><infon key="source">Nat Rev Genet</infon><infon key="type">ref</infon><infon key="lpage">90</infon><offset>25906</offset><text>Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies</text></passage><passage><infon key="volume">75</infon><infon key="name_2">surname:Honigberg;given-names:LA</infon><infon key="name_1">surname:Carlton;given-names:VE</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Begovich;given-names:AB</infon><infon key="fpage">330</infon><infon key="pub-id_pmid">15208781</infon><infon key="year">2004</infon><infon key="source">Am J Hum Genet</infon><infon key="type">ref</infon><infon key="lpage">7</infon><offset>26004</offset><text>A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis</text><annotation id="26530"><infon key="identifier">26191</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7498</infon><location offset="26097" length="6" /><text>PTPN22</text></annotation></passage><passage><infon key="volume">5</infon><infon key="name_2">surname:Spielman;given-names:RS</infon><infon key="name_1">surname:Ewens;given-names:KG</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Onengut-Gumuscu;given-names:S</infon><infon key="fpage">678</infon><infon key="pub-id_pmid">15526003</infon><infon key="year">2004</infon><infon key="source">Genes Immun</infon><infon key="type">ref</infon><infon key="lpage">80</infon><offset>26145</offset><text>A functional polymorphism (1858C/T) in the PTPN22 gene is linked and associated with type I diabetes in multiplex families</text><annotation id="26531"><infon key="identifier">26191</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7498</infon><location offset="26188" length="6" /><text>PTPN22</text></annotation><annotation id="26532"><infon key="identifier">tmVar:c|SUB|C|1858|T;HGVS:c.1858C&gt;T;VariantGroup:3;CorrespondingGene:26191;RS#:2476601;CorrespondingSpecies:9606;CA#:1014942</infon><infon key="type">DNAMutation</infon><location offset="26172" length="7" /><text>1858C/T</text></annotation></passage><passage><infon key="volume">52</infon><infon key="name_2">surname:Gonzalez-Gay;given-names:MA</infon><infon key="name_1">surname:Sanchez;given-names:E</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Orozco;given-names:G</infon><infon key="fpage">219</infon><infon key="pub-id_pmid">15641066</infon><infon key="year">2005</infon><infon key="source">Arthritis Rheum</infon><infon key="type">ref</infon><infon key="lpage">24</infon><offset>26268</offset><text>Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus</text><annotation id="26533"><infon key="identifier">26191</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7498</infon><location offset="26330" length="6" /><text>PTPN22</text></annotation></passage><passage><infon key="volume">357</infon><infon key="name_2">surname:Lee;given-names:AT</infon><infon key="name_1">surname:Plenge;given-names:RM</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Remmers;given-names:EF</infon><infon key="fpage">977</infon><infon key="pub-id_pmid">17804842</infon><infon key="year">2007</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="lpage">86</infon><offset>26436</offset><text>STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus</text><annotation id="26534"><infon key="identifier">6775</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20679</infon><location offset="26436" length="5" /><text>STAT4</text></annotation></passage><passage><infon key="volume">18</infon><infon key="name_2">surname:Simeon;given-names:C</infon><infon key="name_1">surname:Broen;given-names:J</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Rueda;given-names:B</infon><infon key="fpage">2071</infon><infon key="pub-id_pmid">19286670</infon><infon key="year">2009</infon><infon key="source">Hum Mol Genet</infon><infon key="type">ref</infon><infon key="lpage">7</infon><offset>26512</offset><text>The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype</text><annotation id="26535"><infon key="identifier">6775</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20679</infon><location offset="26516" length="5" /><text>STAT4</text></annotation></passage><passage><infon key="volume">40</infon><infon key="name_2">surname:Manku;given-names:H</infon><infon key="name_1">surname:Graham;given-names:RR</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Cunninghame Graham;given-names:DS</infon><infon key="fpage">83</infon><infon key="pub-id_pmid">18059267</infon><infon key="year">2008</infon><infon key="source">Nat Genet</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>26597</offset><text>Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus</text><annotation id="26536"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="26638" length="6" /><text>TNFSF4</text></annotation></passage><passage><infon key="volume">10</infon><infon key="name_2">surname:Zhao;given-names:M</infon><infon key="name_1">surname:Yang;given-names:W</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Chang;given-names:YK</infon><infon key="fpage">414</infon><infon key="pub-id_pmid">19357697</infon><infon key="year">2009</infon><infon key="source">Genes Immun</infon><infon key="type">ref</infon><infon key="lpage">20</infon><offset>26700</offset><text>Association of BANK1 and TNFSF4 with systemic lupus erythematosus in Hong Kong Chinese</text><annotation id="26537"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="26725" length="6" /><text>TNFSF4</text></annotation></passage><passage><infon key="volume">54</infon><infon key="name_2">surname:Rose;given-names:L</infon><infon key="name_1">surname:Eriksson;given-names:P</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Malarstig;given-names:A</infon><infon key="fpage">833</infon><infon key="pub-id_pmid">18356244</infon><infon key="year">2008</infon><infon key="source">Clin Chem</infon><infon key="type">ref</infon><infon key="lpage">40</infon><offset>26787</offset><text>Genetic variants of tumor necrosis factor superfamily, member 4 (TNFSF4), and risk of incident atherothrombosis and venous thromboembolism</text><annotation id="26538"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="26852" length="6" /><text>TNFSF4</text></annotation></passage><passage><infon key="volume">54</infon><infon key="name_2">surname:Rose;given-names:L</infon><infon key="name_1">surname:Eriksson;given-names:P</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Malarstig;given-names:A</infon><infon key="fpage">833</infon><infon key="pub-id_pmid">18356244</infon><infon key="year">2008</infon><infon key="source">Clin Chem</infon><infon key="type">ref</infon><infon key="lpage">40</infon><offset>26926</offset><text>Genetic variants of tumor necrosis factor superfamily, member 4 (TNFSF4), and risk of incident atherothrombosis and venous thromboembolism</text><annotation id="26539"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="26991" length="6" /><text>TNFSF4</text></annotation></passage><passage><infon key="volume">87</infon><infon key="name_2">surname:Jern;given-names:C</infon><infon key="name_1">surname:Soderstrom;given-names:LA</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Olofsson;given-names:PS</infon><infon key="fpage">337</infon><infon key="pub-id_pmid">18998106</infon><infon key="year">2009</infon><infon key="source">J Mol Med</infon><infon key="type">ref</infon><infon key="lpage">46</infon><offset>27065</offset><text>Genetic variants of TNFSF4 and risk for carotid artery disease and stroke</text><annotation id="26540"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="27085" length="6" /><text>TNFSF4</text></annotation></passage><passage><infon key="volume">37</infon><infon key="name_2">surname:Kelmenson;given-names:PM</infon><infon key="name_1">surname:Ria;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Wang;given-names:X</infon><infon key="fpage">365</infon><infon key="pub-id_pmid">15750594</infon><infon key="year">2005</infon><infon key="source">Nat Genet</infon><infon key="type">ref</infon><infon key="lpage">72</infon><offset>27139</offset><text>Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility</text><annotation id="26541"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="27168" length="6" /><text>TNFSF4</text></annotation><annotation id="26542"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="27185" length="11" /><text>OX40 ligand</text></annotation></passage><passage><infon key="volume">367</infon><infon key="name_2">surname:Furst;given-names:DE</infon><infon key="name_1">surname:Clements;given-names:P</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Charles;given-names:C</infon><infon key="fpage">1683</infon><infon key="pub-id_pmid">16714190</infon><infon key="year">2006</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="lpage">91</infon><offset>27255</offset><text>Systemic sclerosis: hypothesis-driven treatment strategies</text></passage><passage><infon key="volume">30</infon><infon key="name_2">surname:McNearney;given-names:T</infon><infon key="name_1">surname:Fischbach;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Reveille;given-names:JD</infon><infon key="fpage">332</infon><infon key="pub-id_pmid">11303306</infon><infon key="year">2001</infon><infon key="source">Semin Arthritis Rheum</infon><infon key="type">ref</infon><infon key="lpage">46</infon><offset>27314</offset><text>Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants</text></passage><passage><infon key="volume">100</infon><infon key="name_2">surname:Karypis;given-names:G</infon><infon key="name_1">surname:Batliwalla;given-names:FM</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Baechler;given-names:EC</infon><infon key="fpage">2610</infon><infon key="pub-id_pmid">12604793</infon><infon key="year">2003</infon><infon key="source">Proc Natl Acad Sci USA</infon><infon key="type">ref</infon><infon key="lpage">15</infon><offset>27442</offset><text>Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus</text></passage><passage><infon key="volume">54</infon><infon key="name_2">surname:Lee;given-names:C</infon><infon key="name_1">surname:Kirou;given-names:K</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Hua;given-names:J</infon><infon key="fpage">1906</infon><infon key="pub-id_pmid">16736505</infon><infon key="year">2006</infon><infon key="source">Arthritis Rheum</infon><infon key="type">ref</infon><infon key="lpage">16</infon><offset>27545</offset><text>Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies</text></passage><passage><infon key="volume">45</infon><infon key="name_2">surname:Mayes;given-names:MD</infon><infon key="name_1">surname:Zhou;given-names:X</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Tan;given-names:FK</infon><infon key="fpage">694</infon><infon key="pub-id_pmid">16418202</infon><infon key="year">2006</infon><infon key="source">Rheumatology (Oxford)</infon><infon key="type">ref</infon><infon key="lpage">702</infon><offset>27683</offset><text>Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients</text></passage><passage><infon key="volume">104</infon><infon key="name_2">surname:Sigurdsson;given-names:S</infon><infon key="name_1">surname:Kyogoku;given-names:C</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Graham;given-names:RR</infon><infon key="fpage">6758</infon><infon key="pub-id_pmid">17412832</infon><infon key="year">2007</infon><infon key="source">Proc Natl Acad Sci USA</infon><infon key="type">ref</infon><infon key="lpage">63</infon><offset>27830</offset><text>Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus</text><annotation id="26543"><infon key="identifier">3663</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8088</infon><location offset="27884" length="4" /><text>IRF5</text></annotation></passage><passage><infon key="volume">60</infon><infon key="name_2">surname:Wipff;given-names:J</infon><infon key="name_1">surname:Guedj;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Dieude;given-names:P</infon><infon key="fpage">225</infon><infon key="pub-id_pmid">19116937</infon><infon key="year">2009</infon><infon key="source">Arthritis Rheum</infon><infon key="type">ref</infon><infon key="lpage">33</infon><offset>27944</offset><text>Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis</text><annotation id="26544"><infon key="identifier">3663</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8088</infon><location offset="27968" length="4" /><text>IRF5</text></annotation><annotation id="26545"><infon key="identifier">tmVar:rs2004640;VariantGroup:1;CorrespondingGene:3663;RS#:2004640;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="27973" length="9" /><text>rs2004640</text></annotation></passage><passage><infon key="volume">54</infon><infon key="name_2">surname:Assassi;given-names:S</infon><infon key="name_1">surname:Tan;given-names:FK</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Gourh;given-names:P</infon><infon key="fpage">3945</infon><infon key="pub-id_pmid">17133608</infon><infon key="year">2006</infon><infon key="source">Arthritis Rheum</infon><infon key="type">ref</infon><infon key="lpage">53</infon><offset>28072</offset><text>Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anti-centromere antibody-positive systemic sclerosis</text><annotation id="26546"><infon key="identifier">26191</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7498</infon><location offset="28091" length="6" /><text>PTPN22</text></annotation><annotation id="26547"><infon key="identifier">tmVar:p|SUB|R|620|W;HGVS:p.R620W;VariantGroup:3;CorrespondingGene:26191;RS#:2476601;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="28098" length="5" /><text>R620W</text></annotation></passage><passage><infon key="volume">68</infon><infon key="name_2">surname:Pacini;given-names:A</infon><infon key="name_1">surname:Manetti;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Liakouli;given-names:V</infon><infon key="fpage">584</infon><infon key="pub-id_pmid">18445624</infon><infon key="year">2009</infon><infon key="source">Ann Rheum Dis</infon><infon key="type">ref</infon><infon key="lpage">90</infon><offset>28201</offset><text>The -670G&gt;A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis</text><annotation id="26548"><infon key="identifier">355</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">27</infon><location offset="28233" length="3" /><text>FAS</text></annotation><annotation id="26549"><infon key="identifier">tmVar:c|SUB|G|-670|A;HGVS:c.-670G&gt;A;VariantGroup:6;CorrespondingGene:355;RS#:1800682;CorrespondingSpecies:9606;CA#:13226452</infon><infon key="type">DNAMutation</infon><location offset="28205" length="7" /><text>-670G&gt;A</text></annotation></passage><passage><infon key="volume">29</infon><infon key="name_2">surname:Saifddin;given-names:A</infon><infon key="name_1">surname:Ihara;given-names:K</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Kanemitsu;given-names:S</infon><infon key="fpage">1183</infon><infon key="pub-id_pmid">12064832</infon><infon key="year">2002</infon><infon key="source">J Rheumatol</infon><infon key="type">ref</infon><infon key="lpage">8</infon><offset>28310</offset><text>A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus</text><annotation id="26550"><infon key="identifier">355</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">27</infon><location offset="28339" length="3" /><text>fas</text></annotation></passage><passage><infon key="volume">28</infon><infon key="name_2">surname:Ji;given-names:JD</infon><infon key="name_1">surname:Kim;given-names:YR</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Lee;given-names:YH</infon><infon key="fpage">2008</infon><infon key="pub-id_pmid">11550967</infon><infon key="year">2001</infon><infon key="source">J Rheumatol</infon><infon key="type">ref</infon><infon key="lpage">11</infon><offset>28415</offset><text>Fas promoter -670 polymorphism is associated with development of anti-RNP antibodies in systemic lupus erythematosus</text><annotation id="26551"><infon key="identifier">355</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">27</infon><location offset="28415" length="3" /><text>Fas</text></annotation></passage><passage><infon key="volume">2</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Mayes;given-names:MD</infon><infon key="fpage">512</infon><infon key="pub-id_pmid">11123106</infon><infon key="year">2000</infon><infon key="source">Curr Rheumatol Rep</infon><infon key="type">ref</infon><infon key="lpage">16</infon><offset>28532</offset><text>The establishment and utility of a population-based registry to understand the epidemiology of systemic sclerosis</text></passage><passage><infon key="volume">39</infon><infon key="name_2">surname:Goldstein;given-names:R</infon><infon key="name_1">surname:Reveille;given-names:JD</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Arnett;given-names:FC</infon><infon key="fpage">1151</infon><infon key="pub-id_pmid">8670324</infon><infon key="year">1996</infon><infon key="source">Arthritis Rheum</infon><infon key="type">ref</infon><infon key="lpage">60</infon><offset>28646</offset><text>Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis</text></passage><passage><infon key="volume">23</infon><infon key="section_type">REF</infon><infon key="fpage">581</infon><infon key="pub-id_pmid">7378088</infon><infon key="year">1980</infon><infon key="source">Arthritis Rheum</infon><infon key="type">ref</infon><infon key="lpage">90</infon><offset>28764</offset><text>Preliminary criteria for the classification of systemic sclerosis (scleroderma)</text></passage><passage><infon key="volume">36</infon><infon key="name_2">surname:Wigley;given-names:FM</infon><infon key="name_1">surname:Hall;given-names:A</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Hummers;given-names:LK</infon><infon key="fpage">576</infon><infon key="pub-id_pmid">19228661</infon><infon key="year">2009</infon><infon key="source">J Rheumatol</infon><infon key="type">ref</infon><infon key="lpage">82</infon><offset>28844</offset><text>Abnormalities in the regulators of angiogenesis in patients with scleroderma</text></passage><passage><infon key="volume">56</infon><infon key="name_2">surname:Reveille;given-names:JD</infon><infon key="name_1">surname:Arnett;given-names:FC</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Assassi;given-names:S</infon><infon key="fpage">2031</infon><infon key="pub-id_pmid">17530643</infon><infon key="year">2007</infon><infon key="source">Arthritis Rheum</infon><infon key="type">ref</infon><infon key="lpage">7</infon><offset>28921</offset><text>Clinical, immunologic, and genetic features of familial systemic sclerosis</text></passage><passage><infon key="volume">15</infon><infon key="name_2">surname:Fleischmajer;given-names:R</infon><infon key="name_1">surname:Black;given-names:C</infon><infon key="section_type">REF</infon><infon key="name_0">surname:LeRoy;given-names:EC</infon><infon key="fpage">202</infon><infon key="pub-id_pmid">3361530</infon><infon key="year">1988</infon><infon key="source">J Rheumatol</infon><infon key="type">ref</infon><infon key="lpage">5</infon><offset>28996</offset><text>Scleroderma (systemic sclerosis): classification, subsets and pathogenesis</text></passage><passage><infon key="volume">69</infon><infon key="name_1">surname:Kinsella;given-names:TD</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Fritzler;given-names:MJ</infon><infon key="fpage">520</infon><infon key="pub-id_pmid">6968511</infon><infon key="year">1980</infon><infon key="source">Am J Med</infon><infon key="type">ref</infon><infon key="lpage">6</infon><offset>29071</offset><text>The CREST syndrome: a distinct serologic entity with anticentromere antibodies</text></passage><passage><infon key="volume">57</infon><infon key="name_1">surname:Hochberg;given-names:Y</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Benjamini;given-names:Y</infon><infon key="fpage">289</infon><infon key="year">1995</infon><infon key="source">Journal of the Royal Statistical Society</infon><infon key="type">ref</infon><infon key="lpage">300</infon><offset>29150</offset><text>Controlling the false discovery rate: a practical and powerful approach to multiple testing</text></passage><passage><infon key="volume">19</infon><infon key="name_1">surname:Bonney;given-names:G</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Zhang;given-names:H</infon><infon key="fpage">323</infon><infon key="pub-id_pmid">11108642</infon><infon key="year">2000</infon><infon key="source">Genet Epidemiol</infon><infon key="type">ref</infon><infon key="lpage">32</infon><offset>29242</offset><text>Use of classification trees for association studies</text></passage><passage><infon key="volume">34</infon><infon key="name_2">surname:Lucas;given-names:M</infon><infon key="name_1">surname:Fertig;given-names:N</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Meyer;given-names:OC</infon><infon key="fpage">104</infon><infon key="pub-id_pmid">17117486</infon><infon key="year">2007</infon><infon key="source">J Rheumatol</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>29294</offset><text>Disease subsets, anti-nuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis</text></passage><passage><infon key="volume">46</infon><infon key="name_2">surname:Tan;given-names:FK</infon><infon key="name_1">surname:Gourh;given-names:P</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Alkassab;given-names:F</infon><infon key="fpage">1248</infon><infon key="pub-id_pmid">17522098</infon><infon key="year">2007</infon><infon key="source">Rheumatology (Oxford)</infon><infon key="type">ref</infon><infon key="lpage">51</infon><offset>29428</offset><text>An allograft inflammatory factor 1 (AIF1) single nucleotide polymorphism (SNP) is associated with anti-centromere antibody positive systemic sclerosis</text><annotation id="26552"><infon key="identifier">199</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1226</infon><location offset="29464" length="4" /><text>AIF1</text></annotation></passage><passage><infon key="volume">78</infon><infon key="name_2">surname:Grossman;given-names:HB</infon><infon key="name_1">surname:Gu;given-names:J</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Wu;given-names:X</infon><infon key="fpage">464</infon><infon key="pub-id_pmid">16465622</infon><infon key="year">2006</infon><infon key="source">Am J Hum Genet</infon><infon key="type">ref</infon><infon key="lpage">79</infon><offset>29579</offset><text>Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes</text></passage><passage><infon key="volume">9</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Croft;given-names:M</infon><infon key="fpage">271</infon><infon key="pub-id_pmid">19319144</infon><infon key="year">2009</infon><infon key="source">Nat Rev Immunol</infon><infon key="type">ref</infon><infon key="lpage">85</infon><offset>29675</offset><text>The role of TNF superfamily members in T-cell function and diseases</text></passage><passage><infon key="volume">179</infon><infon key="name_2">surname:Worsley;given-names:AG</infon><infon key="name_1">surname:Perona-Wright;given-names:G</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Jenkins;given-names:SJ</infon><infon key="fpage">3515</infon><infon key="pub-id_pmid">17785785</infon><infon key="year">2007</infon><infon key="source">J Immunol</infon><infon key="type">ref</infon><infon key="lpage">23</infon><offset>29743</offset><text>Dendritic cell expression of OX40 ligand acts as a costimulatory, not polarising, signal for optimal Th-2 priming and memory induction in vivo</text><annotation id="26553"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="29772" length="11" /><text>OX40 ligand</text></annotation></passage><passage><infon key="volume">33</infon><infon key="name_2">surname:Akiba;given-names:H</infon><infon key="name_1">surname:Tanaka;given-names:Y</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Hoshino;given-names:A</infon><infon key="fpage">861</infon><infon key="pub-id_pmid">12672051</infon><infon key="year">2003</infon><infon key="source">Eur J Immunol</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>29886</offset><text>Critical role for OX40 ligand in the development of pathogenic Th-2 cells in a murine model of asthma</text><annotation id="26554"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="29904" length="11" /><text>OX40 ligand</text></annotation></passage><passage><infon key="volume">253</infon><infon key="name_2">surname:Shang;given-names:X</infon><infon key="name_1">surname:Li;given-names:L</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Li;given-names:J</infon><infon key="fpage">31</infon><infon key="pub-id_pmid">18501882</infon><infon key="year">2008</infon><infon key="source">Cell Immunol</infon><infon key="type">ref</infon><infon key="lpage">7</infon><offset>29988</offset><text>Negative regulation of IL-17 production by OX40/OX40L interaction</text><annotation id="26555"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="30031" length="4" /><text>OX40</text></annotation><annotation id="26556"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="30036" length="5" /><text>OX40L</text></annotation></passage><passage><infon key="volume">181</infon><infon key="name_2">surname:Gao;given-names:W</infon><infon key="name_1">surname:Kroemer;given-names:A</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Xiao;given-names:X</infon><infon key="fpage">3193</infon><infon key="pub-id_pmid">18713990</infon><infon key="year">2008</infon><infon key="source">J Immunol</infon><infon key="type">ref</infon><infon key="lpage">201</infon><offset>30054</offset><text>OX40/OX40L costimulation affects induction of Foxp3+ regulatory T-cells in part by expanding memory T-cells in vivo</text><annotation id="26557"><infon key="identifier">50943</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8516</infon><location offset="30100" length="5" /><text>Foxp3</text></annotation><annotation id="26558"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="30054" length="4" /><text>OX40</text></annotation><annotation id="26559"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="30059" length="5" /><text>OX40L</text></annotation></passage><passage><infon key="volume">24</infon><infon key="name_2">surname:Ishii;given-names:N</infon><infon key="name_1">surname:Kojima;given-names:H</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Kato;given-names:H</infon><infon key="fpage">237</infon><infon key="pub-id_pmid">15114054</infon><infon key="year">2004</infon><infon key="source">J Clin Immunol</infon><infon key="type">ref</infon><infon key="lpage">48</infon><offset>30170</offset><text>Essential role of OX40L on B cells in persistent alloantibody production following repeated alloimmunisations</text><annotation id="26560"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="30188" length="5" /><text>OX40L</text></annotation></passage><passage><infon key="volume">2</infon><infon key="name_2">surname:Calderhead;given-names:D</infon><infon key="name_1">surname:Neurath;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Stuber;given-names:E</infon><infon key="fpage">507</infon><infon key="pub-id_pmid">7749983</infon><infon key="year">1995</infon><infon key="source">Immunity</infon><infon key="type">ref</infon><infon key="lpage">21</infon><offset>30280</offset><text>Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells</text><annotation id="26561"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="30297" length="11" /><text>OX40 ligand</text></annotation></passage><passage><infon key="volume">183</infon><infon key="name_1">surname:Strober;given-names:W</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Stuber;given-names:E</infon><infon key="fpage">979</infon><infon key="pub-id_pmid">8642301</infon><infon key="year">1996</infon><infon key="source">J Exp Med</infon><infon key="type">ref</infon><infon key="lpage">89</infon><offset>30419</offset><text>The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response</text><annotation id="26562"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="30453" length="4" /><text>OX40</text></annotation><annotation id="26563"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="30458" length="5" /><text>OX40L</text></annotation></passage><passage><infon key="volume">172</infon><infon key="name_2">surname:Inaba;given-names:M</infon><infon key="name_1">surname:Amakawa;given-names:R</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Ito;given-names:T</infon><infon key="fpage">4253</infon><infon key="pub-id_pmid">15034038</infon><infon key="year">2004</infon><infon key="source">J Immunol</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>30526</offset><text>Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs</text><annotation id="26564"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="30590" length="11" /><text>OX40 ligand</text></annotation></passage><passage><infon key="volume">169</infon><infon key="name_2">surname:Ndhlovu;given-names:LC</infon><infon key="name_1">surname:Nose;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Murata;given-names:K</infon><infon key="fpage">4628</infon><infon key="pub-id_pmid">12370402</infon><infon key="year">2002</infon><infon key="source">J Immunol</infon><infon key="type">ref</infon><infon key="lpage">36</infon><offset>30618</offset><text>Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases</text><annotation id="26565"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="30636" length="11" /><text>OX40 ligand</text></annotation><annotation id="26566"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="30631" length="4" /><text>OX40</text></annotation></passage><passage><infon key="volume">34</infon><infon key="name_2">surname:Halteman;given-names:BS</infon><infon key="name_1">surname:Bansal-Pakala;given-names:P</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Pakala;given-names:SV</infon><infon key="fpage">3039</infon><infon key="pub-id_pmid">15368274</infon><infon key="year">2004</infon><infon key="source">Eur J Immunol</infon><infon key="type">ref</infon><infon key="lpage">46</infon><offset>30693</offset><text>Prevention of diabetes in NOD mice at a late stage by targeting OX40/OX40 ligand interactions</text><annotation id="26567"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="30762" length="11" /><text>OX40 ligand</text></annotation><annotation id="26568"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="30757" length="4" /><text>OX40</text></annotation></passage><passage><infon key="volume">166</infon><infon key="name_2">surname:Nakajima;given-names:A</infon><infon key="name_1">surname:Akiba;given-names:H</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Nohara;given-names:C</infon><infon key="fpage">2108</infon><infon key="pub-id_pmid">11160262</infon><infon key="year">2001</infon><infon key="source">J Immunol</infon><infon key="type">ref</infon><infon key="lpage">15</infon><offset>30787</offset><text>Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells</text><annotation id="26569"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="30908" length="11" /><text>OX40 ligand</text></annotation><annotation id="26570"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="30855" length="11" /><text>OX40 ligand</text></annotation></passage><passage><infon key="volume">35</infon><infon key="name_2">surname:Kodera;given-names:M</infon><infon key="name_1">surname:Yoshizaki;given-names:A</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Komura;given-names:K</infon><infon key="fpage">2359</infon><infon key="pub-id_pmid">18843780</infon><infon key="year">2008</infon><infon key="source">J Rheumatol</infon><infon key="type">ref</infon><infon key="lpage">62</infon><offset>30977</offset><text>Increased serum soluble OX40 in patients with systemic sclerosis</text><annotation id="26571"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="31001" length="4" /><text>OX40</text></annotation></passage><passage><infon key="volume">90</infon><infon key="name_2">surname:MacLeod-St Clair;given-names:MJ</infon><infon key="name_1">surname:Durban;given-names:E</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Reveille;given-names:JD</infon><infon key="fpage">973</infon><infon key="pub-id_pmid">1326003</infon><infon key="year">1992</infon><infon key="source">J Clin Invest</infon><infon key="type">ref</infon><infon key="lpage">80</infon><offset>31042</offset><text>Association of amino acid sequences in the HLA-DQB1 first domain with anti-topoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis)</text></passage><relation id="R1"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D012595</infon><infon key="role2">Gene|7292</infon><infon key="type">Association</infon></relation><relation id="R2"><infon key="score">0.9978</infon><infon key="role1">Disease|MESH:D012595</infon><infon key="role2">Gene|7292</infon><infon key="type">Association</infon></relation><relation id="R3"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D008180</infon><infon key="role2">Gene|7292</infon><infon key="type">Association</infon></relation><relation id="R4"><infon key="score">0.998</infon><infon key="role1">Disease|MESH:D012595</infon><infon key="role2">SNP|RS#:2205960</infon><infon key="type">Positive_Correlation</infon></relation><relation id="R5"><infon key="score">0.9972</infon><infon key="role1">Disease|MESH:D012595</infon><infon key="role2">SNP|RS#:844648;CorrespondingGene:100506023</infon><infon key="type">Positive_Correlation</infon></relation><relation id="R6"><infon key="score">0.9796</infon><infon key="role1">Disease|MESH:D012595</infon><infon key="role2">SNP|RS#:844644;CorrespondingGene:100506023</infon><infon key="type">Negative_Correlation</infon></relation><relation id="R7"><infon key="score">0.994</infon><infon key="role1">Disease|MESH:D005355</infon><infon key="role2">Gene|7292</infon><infon key="type">Association</infon></relation><relation id="R8"><infon key="score">0.9978</infon><infon key="role1">Disease|MESH:D012595</infon><infon key="role2">SNP|RS#:1234314;CorrespondingGene:7292</infon><infon key="type">Positive_Correlation</infon></relation><relation id="R9"><infon key="score">0.9972</infon><infon key="role1">Disease|MESH:D012595</infon><infon key="role2">Gene|100506023</infon><infon key="type">Association</infon></relation></document>
<document><id>9128899</id><passage><infon key="name_3">surname:NYGAARD;given-names:Uffe</infon><infon key="name_2">surname:STOUGAARD;given-names:Julie Kristine</infon><infon key="name_1">surname:CARLSSON;given-names:Michael</infon><infon key="name_0">surname:ELSNER;given-names:Julie Sophie Hohwu</infon><infon key="issue">6</infon><infon key="year">2020</infon><infon key="article-id_publisher-id">ActaDV-2020-6-5712</infon><infon key="article-id_doi">10.2340/00015555-3452</infon><infon key="title">Key words</infon><infon key="type">front</infon><infon key="elocation-id">5712</infon><infon key="volume">100</infon><infon key="license">This is an open access article under the CC BY-NC license</infon><infon key="section_type">TITLE</infon><infon key="kwd">atopic dermatitis OX40 OX40L</infon><infon key="name_9">surname:DELEURAN;given-names:Bent</infon><infon key="name_8">surname:DELEURAN;given-names:Mette</infon><infon key="name_7">surname:VESTERGAARD;given-names:Christian</infon><infon key="name_6">surname:HVID;given-names:Malene</infon><infon key="name_5">surname:FOLSTER-HOLST;given-names:Regina</infon><infon key="name_4">surname:BUCHNER;given-names:Matthias</infon><infon key="article-id_pmc">9128899</infon><infon key="article-id_pmid">32176307</infon><offset>0</offset><text>The OX40 Axis is Associated with Both Systemic and Local Involvement in Atopic Dermatitis</text><annotation id="3829"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="4" length="4" /><text>OX40</text></annotation><annotation id="3830"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="72" length="17" /><text>Atopic Dermatitis</text></annotation></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>90</offset><text>Atopic dermatitis (AD) is a chronic, or chronically relapsing, inflammatory skin disease associated with asthma and allergic rhinitis, and is dominated by Th2 cells. The co-stimulatory T-cell receptor OX40 and its ligand, OX40L, play a central role in the pathogenesis of AD, as their interactions are crucial for the generation of TH2 memory cells. Using enzyme-linked immunoassay (ELISA) and flow cytometry on blood samples from patients with AD and healthy volunteers, this study shows that the serum level of soluble (s) OX40 is decreased in patients with AD, and the expression of OX40 by activated skin-homing CD4+ T cells is increased. This study further shows, using immunofluorescence on skin biopsies, that OX40+ and OX40L+ cells are co-located within the dermis, indicating local activity of OX40/OX40L. Serum levels of sOX40 were associated with atopic diseases and, together, these results support that the OX40 system is important for chronic inflammation in AD skin.</text><annotation id="3831"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="291" length="4" /><text>OX40</text></annotation><annotation id="3832"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="312" length="5" /><text>OX40L</text></annotation><annotation id="3833"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="615" length="4" /><text>OX40</text></annotation><annotation id="3834"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="676" length="4" /><text>OX40</text></annotation><annotation id="3835"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="706" length="3" /><text>CD4</text></annotation><annotation id="3836"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="807" length="4" /><text>OX40</text></annotation><annotation id="3837"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="817" length="5" /><text>OX40L</text></annotation><annotation id="3838"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="893" length="4" /><text>OX40</text></annotation><annotation id="3839"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="898" length="6" /><text>OX40L.</text></annotation><annotation id="3840"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="1010" length="4" /><text>OX40</text></annotation><annotation id="3841"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="521" length="8" /><text>patients</text></annotation><annotation id="3842"><infon key="identifier">MESH:D065631</infon><infon key="type">Disease</infon><location offset="206" length="17" /><text>allergic rhinitis</text></annotation><annotation id="3843"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="195" length="6" /><text>asthma</text></annotation><annotation id="3844"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="650" length="2" /><text>AD</text></annotation><annotation id="3845"><infon key="identifier">MESH:D012871</infon><infon key="type">Disease</infon><location offset="153" length="25" /><text>inflammatory skin disease</text></annotation><annotation id="3846"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="362" length="2" /><text>AD</text></annotation><annotation id="3847"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1039" length="20" /><text>chronic inflammation</text></annotation><annotation id="3848"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="109" length="2" /><text>AD</text></annotation><annotation id="3849"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="1063" length="2" /><text>AD</text></annotation><annotation id="3850"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="535" length="2" /><text>AD</text></annotation><annotation id="3851"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="636" length="8" /><text>patients</text></annotation><annotation id="3852"><infon key="identifier">MESH:D006969</infon><infon key="type">Disease</infon><location offset="948" length="15" /><text>atopic diseases</text></annotation><annotation id="3853"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="90" length="17" /><text>Atopic dermatitis</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1072</offset><text>Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects up to 20% of children and may persist into adulthood. The symptoms are eczema, intense pruritus, and dry skin, caused by a profound skin inflammation and epidermal barrier dysfunction. Up to 80% of patients with AD have elevated levels of IgE. Furthermore, development of memory T cells is believed to be central for chronicity in AD.</text><annotation id="3854"><infon key="identifier">3497</infon><infon key="type">Gene</infon><location offset="1386" length="4" /><text>IgE.</text></annotation><annotation id="3855"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="1478" length="2" /><text>AD</text></annotation><annotation id="3856"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="1359" length="2" /><text>AD</text></annotation><annotation id="3857"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="1345" length="8" /><text>patients</text></annotation><annotation id="3858"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="1091" length="2" /><text>AD</text></annotation><annotation id="3859"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="1072" length="17" /><text>Atopic dermatitis</text></annotation><annotation id="3860"><infon key="identifier">MESH:D012871</infon><infon key="type">Disease</infon><location offset="1108" length="25" /><text>inflammatory skin disease</text></annotation><annotation id="3861"><infon key="identifier">MESH:D011537</infon><infon key="type">Disease</infon><location offset="1234" length="8" /><text>pruritus</text></annotation><annotation id="3862"><infon key="identifier">MESH:D015352</infon><infon key="type">Disease</infon><location offset="1248" length="8" /><text>dry skin</text></annotation><annotation id="3863"><infon key="identifier">MESH:D004485</infon><infon key="type">Disease</infon><location offset="1218" length="6" /><text>eczema</text></annotation><annotation id="3864"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1279" length="17" /><text>skin inflammation</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1482</offset><text>OX40 and its ligand, OX40L, are both members of the tumour necrosis factor superfamily and are important regulators of the immune response. The OX40 system is required for generating a long-term memory response and optimal T-cell activation. The OX40-OX40L axis is considered to be involved in the development of autoimmune and inflammatory conditions, including allergic asthma.</text><annotation id="3865"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="1482" length="4" /><text>OX40</text></annotation><annotation id="3866"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="1503" length="5" /><text>OX40L</text></annotation><annotation id="3867"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="1626" length="4" /><text>OX40</text></annotation><annotation id="3868"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="1728" length="4" /><text>OX40</text></annotation><annotation id="3869"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="1733" length="5" /><text>OX40L</text></annotation><annotation id="3870"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="1854" length="6" /><text>asthma</text></annotation><annotation id="3871"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1795" length="38" /><text>autoimmune and inflammatory conditions</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1862</offset><text>T-cell expression of OX40 and antigen-presenting cells (APC) expression of OX40L appear within 2-3 days after antigen-activation. The signal through OX40 enhances T-cell clonal expansion and, especially, survival of TH2 cells. Apart from APC, OX40L is also expressed by mast cells. Both OX40 and OX40L also exist in soluble forms. Soluble OX40 (sOX40) has an anti-inflammatory effect when binding to the membrane-bound form of OX40L. sOX40 is able to mimic regulatory T-cell function, inhibit mast cell degranulation and thereby reduce the inflammatory response.</text><annotation id="3872"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="1883" length="4" /><text>OX40</text></annotation><annotation id="3873"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="1937" length="5" /><text>OX40L</text></annotation><annotation id="3874"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="2011" length="4" /><text>OX40</text></annotation><annotation id="3875"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="2105" length="5" /><text>OX40L</text></annotation><annotation id="3876"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="2149" length="4" /><text>OX40</text></annotation><annotation id="3877"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="2158" length="5" /><text>OX40L</text></annotation><annotation id="3878"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="2201" length="4" /><text>OX40</text></annotation><annotation id="3879"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="2289" length="6" /><text>OX40L.</text></annotation><annotation id="3880"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="2402" length="12" /><text>inflammatory</text></annotation><annotation id="3881"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="2226" length="12" /><text>inflammatory</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2427</offset><text>SIGNIFICANCE</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2440</offset><text>Atopic dermatitis is a chronic, or chronically relapsing, inflammatory skin disease dominated by Th2 cells. The costimulatory T-cell receptor OX40 and its ligand, OX40L, are crucial for the generation of Th2 memory cells, and may thus play a central role in the pathogenesis and chronicity of atopic dermatitis. This study shows that OX40 expression is increased on skin-homing T cells in patients with atopic dermatitis, and that OX40 and OX40L cells are colocalized in the skin. These findings indicate that the OX40 system could play a pivotal role in the inflammatory reaction of atopic dermatitis in the skin.</text><annotation id="3882"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="2582" length="4" /><text>OX40</text></annotation><annotation id="3883"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="2603" length="5" /><text>OX40L</text></annotation><annotation id="3884"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="2774" length="4" /><text>OX40</text></annotation><annotation id="3885"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="2871" length="4" /><text>OX40</text></annotation><annotation id="3886"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="2880" length="5" /><text>OX40L</text></annotation><annotation id="3887"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="2954" length="4" /><text>OX40</text></annotation><annotation id="3888"><infon key="identifier">MESH:D012871</infon><infon key="type">Disease</infon><location offset="2498" length="25" /><text>inflammatory skin disease</text></annotation><annotation id="3889"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="2733" length="17" /><text>atopic dermatitis</text></annotation><annotation id="3890"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="2440" length="17" /><text>Atopic dermatitis</text></annotation><annotation id="3891"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="2999" length="12" /><text>inflammatory</text></annotation><annotation id="3892"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="3024" length="17" /><text>atopic dermatitis</text></annotation><annotation id="3893"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="2829" length="8" /><text>patients</text></annotation><annotation id="3894"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="2843" length="17" /><text>atopic dermatitis</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3055</offset><text>Not only are mast cells implicated in the immediate hypersensitivity reactions, but also in the production of TH2 driving cytokines, such as interleukin (IL)-4 and IL-25, and hence central mediators of AD pathogenesis.</text><annotation id="3895"><infon key="identifier">64806</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">15429</infon><location offset="3219" length="5" /><text>IL-25</text></annotation><annotation id="3896"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="3257" length="2" /><text>AD</text></annotation><annotation id="3897"><infon key="identifier">MESH:D004342</infon><infon key="type">Disease</infon><location offset="3107" length="16" /><text>hypersensitivity</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3274</offset><text>Furthermore, IgE-activated mast cells have been shown to interact with T cells through expression of OX40L, suggesting a sophisticated interplay between these immune cells mediated by IgE and OX40L.</text><annotation id="3898"><infon key="identifier">3497</infon><infon key="type">Gene</infon><location offset="3287" length="3" /><text>IgE</text></annotation><annotation id="3899"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="3375" length="5" /><text>OX40L</text></annotation><annotation id="3900"><infon key="identifier">3497</infon><infon key="type">Gene</infon><location offset="3458" length="3" /><text>IgE</text></annotation><annotation id="3901"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="3466" length="5" /><text>OX40L</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3473</offset><text>The aim of this study was to characterize the OX40/ OX40L axis in AD, including the OX40 expressing cells and the correlation between serum levels and disease-specific markers.</text><annotation id="3902"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="3519" length="4" /><text>OX40</text></annotation><annotation id="3903"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="3525" length="5" /><text>OX40L</text></annotation><annotation id="3904"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="3557" length="4" /><text>OX40</text></annotation><annotation id="3905"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="3539" length="2" /><text>AD</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>3650</offset><text>MATERIALS AND METHODS</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>3672</offset><text>Patient samples</text><annotation id="3906"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="3672" length="7" /><text>Patient</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>3688</offset><text>Patients with AD were diagnosed using the Hanifin &amp; Rajka criteria. None of the patients were receiving systemic immune suppressive therapy at the time of sample collection. All patients were assessed by use of the SCORing Atopic Dermatitis index (SCORAD) and measurement of total IgE serum level.</text><annotation id="3907"><infon key="identifier">3497</infon><infon key="type">Gene</infon><location offset="3969" length="3" /><text>IgE</text></annotation><annotation id="3908"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="3688" length="8" /><text>Patients</text></annotation><annotation id="3909"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="3702" length="2" /><text>AD</text></annotation><annotation id="3910"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="3866" length="8" /><text>patients</text></annotation><annotation id="3911"><infon key="identifier">MESH:D003872</infon><infon key="type">Disease</infon><location offset="3918" length="10" /><text>Dermatitis</text></annotation><annotation id="3912"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="3768" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>3986</offset><text>Serum samples from 67 adults (age 30; range 24-42 years), and 60 children with AD (age 8; 3-14 years) were collected at the Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel, Germany. Clinical parameters were acquired at the time of blood collection: SCORAD, total serum IgE and the presence of asthma and/or rhinitis (Table I). Serum samples were also obtained from 31 healthy controls (HC) (age 39; 28-51 years) matched for age and sex with the adult AD group. The controls had no history of AD or other systemic inflammatory diseases. All adult patients with AD and HC gave their written informed consent. The parents provided written consent on behalf of their children with AD. For ethical reasons serum samples from healthy children were not included.</text><annotation id="3913"><infon key="identifier">3497</infon><infon key="type">Gene</infon><location offset="4286" length="3" /><text>IgE</text></annotation><annotation id="3914"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="4065" length="2" /><text>AD</text></annotation><annotation id="3915"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="4577" length="2" /><text>AD</text></annotation><annotation id="3916"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="4509" length="2" /><text>AD</text></annotation><annotation id="3917"><infon key="identifier">MESH:D018746</infon><infon key="type">Disease</infon><location offset="4521" length="30" /><text>systemic inflammatory diseases</text></annotation><annotation id="3918"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="4563" length="8" /><text>patients</text></annotation><annotation id="3919"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="4310" length="6" /><text>asthma</text></annotation><annotation id="3920"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="4694" length="2" /><text>AD</text></annotation><annotation id="3921"><infon key="identifier">MESH:D012220</infon><infon key="type">Disease</infon><location offset="4324" length="8" /><text>rhinitis</text></annotation><annotation id="3922"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="4468" length="2" /><text>AD</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">t0001.xml</infon><infon key="id">t0001</infon><infon key="type">table_caption</infon><offset>4779</offset><text>Characteristics of patients with atopic dermatitis (AD)</text><annotation id="3923"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="4798" length="8" /><text>patients</text></annotation><annotation id="3924"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="4831" length="2" /><text>AD</text></annotation><annotation id="3925"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="4812" length="17" /><text>atopic dermatitis</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">t0001.xml</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt; &lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;Group&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;Samples &lt;italic&gt;n&lt;/italic&gt;&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;Age, years Median (range)&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;Sex% female (&lt;italic&gt;n&lt;/italic&gt;)&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;SCORAD Median (range)&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;Total IgE (IU/ml) Median (range)&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;Asthma % (&lt;italic&gt;n&lt;/italic&gt;)&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;Rhinitis % (&lt;italic&gt;n&lt;/italic&gt;)&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;Asthma and rhinitis % (&lt;italic&gt;n&lt;/italic&gt;)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left" colspan="9" rowspan="1"&gt;ELISA&lt;sup&gt;&lt;xref rid="tfn0001" ref-type="table-fn"&gt;a&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Children with AD&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;60&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;8 (3-14)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;55.0 (33)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;37.0 (19.9-47.4)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;154.0 (36.50-839.0)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;28.3 (17)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;35.0 (21)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;20.0 (12)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Adults with AD&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;67&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;30(24-42)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;52.2(35)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;32.0 (16.2-44.5)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;198.0 (61.7-802.0)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;35.8 (24)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;64.2 (43)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;35.0 (21)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Healthy controls&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;31&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;39 (28 - 51)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;61.3 (19)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;40.0 (8.0-59.0)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" colspan="9" rowspan="1"&gt;Flow cytometry&lt;sup&gt;&lt;xref rid="tfn0001" ref-type="table-fn"&gt;b&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Adults with AD&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;11&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;29 (21.0-43.0)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;27.3 (3)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;54.6 (43.6-64.3)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;1,458 (357-4352)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;18.1 (2)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;27.3 (3)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;9.1 (1)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Healthy controls&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;10&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;27 (24.0-32.5)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;40.0 (4)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; </infon><infon key="id">t0001</infon><infon key="type">table</infon><offset>4835</offset><text>Group Samples n Age, years Median (range) Sex% female (n) SCORAD Median (range) Total IgE (IU/ml) Median (range) Asthma % (n) Rhinitis % (n) Asthma and rhinitis % (n)   ELISAa    Children with AD 60 8 (3-14) 55.0 (33) 37.0 (19.9-47.4) 154.0 (36.50-839.0) 28.3 (17) 35.0 (21) 20.0 (12)    Adults with AD 67 30(24-42) 52.2(35) 32.0 (16.2-44.5) 198.0 (61.7-802.0) 35.8 (24) 64.2 (43) 35.0 (21)    Healthy controls 31 39 (28 - 51) 61.3 (19) - 40.0 (8.0-59.0) - - -   Flow cytometryb   Adults with AD 11 29 (21.0-43.0) 27.3 (3) 54.6 (43.6-64.3) 1,458 (357-4352) 18.1 (2) 27.3 (3) 9.1 (1)    Healthy controls 10 27 (24.0-32.5) 40.0 (4) - - - - -   </text><annotation id="3926"><infon key="identifier">3497</infon><infon key="type">Gene</infon><location offset="4921" length="3" /><text>IgE</text></annotation><annotation id="3927"><infon key="identifier">MESH:D012220</infon><infon key="type">Disease</infon><location offset="4961" length="8" /><text>Rhinitis</text></annotation><annotation id="3928"><infon key="type">Species</infon><location offset="5316" length="6" /><text>Adults</text></annotation><annotation id="3929"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="5028" length="2" /><text>AD</text></annotation><annotation id="3930"><infon key="identifier">MESH:D012220</infon><infon key="type">Disease</infon><location offset="4987" length="8" /><text>rhinitis</text></annotation><annotation id="3931"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="5328" length="2" /><text>AD</text></annotation><annotation id="3932"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="4948" length="6" /><text>Asthma</text></annotation><annotation id="3933"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="4976" length="6" /><text>Asthma</text></annotation><annotation id="3934"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="5135" length="2" /><text>AD</text></annotation><annotation id="3935"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="5014" length="8" /><text>Children</text></annotation><annotation id="3936"><infon key="type">Species</infon><location offset="5123" length="6" /><text>Adults</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">t0001.xml</infon><infon key="id">t0001</infon><infon key="type">table_footnote</infon><offset>5510</offset><text>Serum samples of patients with AD analysed for levels of sOX40 and sOX40L by enzyme-linked immunoassay (ELISA).</text><annotation id="3937"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="5541" length="2" /><text>AD</text></annotation><annotation id="3938"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="5527" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">t0001.xml</infon><infon key="id">t0001</infon><infon key="type">table_footnote</infon><offset>5622</offset><text>Peripheral blood mononuclear cells from patients with AD analysed for membrane expression of OX40 and OX40L by flow cytometry.</text><annotation id="3939"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="5715" length="4" /><text>OX40</text></annotation><annotation id="3940"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="5724" length="5" /><text>OX40L</text></annotation><annotation id="3941"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="5676" length="2" /><text>AD</text></annotation><annotation id="3942"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="5662" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">t0001.xml</infon><infon key="id">t0001</infon><infon key="type">table_footnote</infon><offset>5749</offset><text>Healthy controls were matched for age and sex to the patients with AD (for the adult group only).</text><annotation id="3943"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="5816" length="2" /><text>AD</text></annotation><annotation id="3944"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="5802" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">t0001.xml</infon><infon key="id">t0001</infon><infon key="type">table_footnote</infon><offset>5847</offset><text>SCORAD: Subjective SCORing Atopic Dermatitis.</text><annotation id="3945"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="5874" length="17" /><text>Atopic Dermatitis</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5893</offset><text>Peripheral blood mononuclear cells (PBMCs) and plasma were collected from 11 adult patients with AD (age 29; 21-43 years) and 10 age- and sex-matched HC (age 27; 24-33 years) with no atopic diseases or systemic inflammatory diseases (Table I). The PBMCs were isolated by Ficoll-Paque (GE Healthcare Europe, Brondby, Denmark) density gradient centrifugation and frozen at -135 C until analysis.</text><annotation id="3946"><infon key="identifier">MESH:D018746</infon><infon key="type">Disease</infon><location offset="6095" length="30" /><text>systemic inflammatory diseases</text></annotation><annotation id="3947"><infon key="identifier">MESH:D006969</infon><infon key="type">Disease</infon><location offset="6076" length="15" /><text>atopic diseases</text></annotation><annotation id="3948"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="5976" length="8" /><text>patients</text></annotation><annotation id="3949"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="5990" length="2" /><text>AD</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6295</offset><text>Paraffin-embedded biopsies were collected from involved and uninvolved skin from 5 patients with AD and skin biopsies were collected from 5 HC. Written consent was obtained in accordance with the guidelines of the Danish National Ethics Committee for Health Research and the principles of the Declaration of Helsinki.</text><annotation id="3950"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="6392" length="2" /><text>AD</text></annotation><annotation id="3951"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="6378" length="8" /><text>patients</text></annotation><annotation id="3952"><infon key="identifier">MESH:D010232</infon><infon key="type">Chemical</infon><location offset="6295" length="8" /><text>Paraffin</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6613</offset><text>Detection of sOX40 and sOX40L by ELISA</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6652</offset><text>Soluble OX40 and sOX40L were measured in serum from patients with AD and from HC with a sOX40 ELISA kit (cat. no. BMS296TEN, eBioscience (eBioscience, San Diego, CA, USA)) and with an inhouse sOX40L ELISA, as described previously. OD values were read by a Thermo Scientific Multiscan GO reader (Thermo Scientific, Waltham, MA, USA) at 450 nm, with 570 nm as a reference. The minimum detectable level of sOX40 and sOX40L was determined by the cut-off value of the standard curve. The lowest detectable levels of sOX40 and sOX40L were 1.9 and 0.039 ng/ml, respectively.</text><annotation id="3953"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="6660" length="4" /><text>OX40</text></annotation><annotation id="3954"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="6757" length="3" /><text>cat</text></annotation><annotation id="3955"><infon key="identifier">MESH:D000067329</infon><infon key="type">Disease</infon><location offset="6730" length="2" /><text>HC</text></annotation><annotation id="3956"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="6766" length="9" /><text>BMS296TEN</text></annotation><annotation id="3957"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="6704" length="8" /><text>patients</text></annotation><annotation id="3958"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="6718" length="2" /><text>AD</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7220</offset><text>Flow cytometry</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7235</offset><text>The expression of OX40 and OX40L on the cell surface were analysed by flow cytometry on PBMCs from patients with AD and HC.</text><annotation id="3959"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="7253" length="4" /><text>OX40</text></annotation><annotation id="3960"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="7262" length="5" /><text>OX40L</text></annotation><annotation id="3961"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="7348" length="2" /><text>AD</text></annotation><annotation id="3962"><infon key="identifier">MESH:D000067329</infon><infon key="type">Disease</infon><location offset="7355" length="2" /><text>HC</text></annotation><annotation id="3963"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="7334" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7359</offset><text>The cells were thawed and blocked with 100 mug/ml mouse IgG (Jackson Immunoresearch Europe Ltd, (JIR), Cambridgeshire, UK) to prevent unspecific binding.</text><annotation id="3964"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="7409" length="5" /><text>mouse</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7513</offset><text>Unstimulated, blocked cells were stained using the following monoclonal antibodies, all titrated for optimal concentration: PE-Cy7-anti CD4 (cat. no. 560649, clone: RPA-T4), BV605-anti CD8 (cat. no. 564116, clone: SK1), BV510-anti CD14 (cat. no. 563079, clone: MPhiP9), PerCP-Cy5.5-anti CD45RO (cat. no. 560607, clone: UCHL1), FITC-anti CD56 (cat. no. 562794, clone: B159), BV 421-anti CLA (cat. no. 563961, clone: HECA-452) (all from BD Biosciences, San Jose, CA, USA), APC-anti OX40 (cat. no. 17-1347, clone: ACT 35, eBioscience), PE-anti OX40L (cat. no. FAB10541p, clone: 159403,R&amp;D Systems, Minneapolis, MN, USA) and LIVE/DEAD Near IR antibody (cat. no. L10119, Life Technologies, Carlsbad, CA, USA) for detection of dead cells. After addition of antibodies the cells were incubated for 30 min in the dark at 4 C and washed 3 times in wash buffer (phosphatebuffered saline (PBS), pH 7.4, supplemented with 0.5% bovine serum albumin (BSA) and 0.09% sodium azide). Cells were fixed in 0.9% formaldehyde and analysed within 24 h on a LSR Fortessa (BD Biosciences) flow cytometer with Diva software (version: BDFacs Diva 8.0 (BD Biosciences)). Data were analysed on FlowJo Software for MAC version 10.1 (Tree Star Inc., Ashland, USA). Fluorescence minus one (FMO) controls were used to gate OX40 and OX40L. Antibody-coated beads (OneComp, eBioscience) were used for compensation of spectral overlap.</text><annotation id="3965"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="7649" length="3" /><text>CD4</text></annotation><annotation id="3966"><infon key="identifier">925</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">133777</infon><location offset="7698" length="3" /><text>CD8</text></annotation><annotation id="3967"><infon key="identifier">929</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">493</infon><location offset="7744" length="4" /><text>CD14</text></annotation><annotation id="3968"><infon key="identifier">5788</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2126</infon><location offset="7800" length="6" /><text>CD45RO</text></annotation><annotation id="3969"><infon key="identifier">7345</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37894</infon><location offset="7832" length="5" /><text>UCHL1</text></annotation><annotation id="3970"><infon key="identifier">4684</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">40754</infon><location offset="7850" length="4" /><text>CD56</text></annotation><annotation id="3971"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="7993" length="4" /><text>OX40</text></annotation><annotation id="3972"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="8054" length="5" /><text>OX40L</text></annotation><annotation id="3973"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="8804" length="4" /><text>OX40</text></annotation><annotation id="3974"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="8813" length="6" /><text>OX40L.</text></annotation><annotation id="3975"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="8162" length="3" /><text>cat</text></annotation><annotation id="3976"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="8061" length="3" /><text>cat</text></annotation><annotation id="3977"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="7999" length="3" /><text>cat</text></annotation><annotation id="3978"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="7904" length="3" /><text>cat</text></annotation><annotation id="3979"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="7856" length="3" /><text>cat</text></annotation><annotation id="3980"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="7808" length="3" /><text>cat</text></annotation><annotation id="3981"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="7750" length="3" /><text>cat</text></annotation><annotation id="3982"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="7703" length="3" /><text>cat</text></annotation><annotation id="3983"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="7654" length="3" /><text>cat</text></annotation><annotation id="3984"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="8391" length="3" /><text>PBS</text></annotation><annotation id="3985"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="7640" length="3" /><text>Cy7</text></annotation><annotation id="3986"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="7733" length="5" /><text>BV510</text></annotation><annotation id="3987"><infon key="identifier">MESH:C000626784</infon><infon key="type">Chemical</infon><location offset="7899" length="3" /><text>CLA</text></annotation><annotation id="3988"><infon key="identifier">MESH:D005557</infon><infon key="type">Chemical</infon><location offset="8505" length="12" /><text>formaldehyde</text></annotation><annotation id="3989"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="7887" length="6" /><text>BV 421</text></annotation><annotation id="3990"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="8365" length="24" /><text>phosphatebuffered saline</text></annotation><annotation id="3991"><infon key="identifier">MESH:D019810</infon><infon key="type">Chemical</infon><location offset="8465" length="12" /><text>sodium azide</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>8915</offset><text>Confocal microscopy</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8935</offset><text>Formaldehyde-fixed, paraffin-embedded skin biopsies from involved and uninvolved skin from 5 adult patients with AD and 5 HC were cut into 5-mum sections using a microtome (version: HM 360, MICROM, Microm UK LTD, Bicester, UK). Slides were deparaffinized in xylene, rehydrated in an ethanol gradient, followed by heat-induced antigen retrieval in citrate-phosphate buffer (pH 6).</text><annotation id="3992"><infon key="identifier">MESH:D010232</infon><infon key="type">Chemical</infon><location offset="8955" length="8" /><text>paraffin</text></annotation><annotation id="3993"><infon key="identifier">MESH:D010710</infon><infon key="type">Chemical</infon><location offset="9290" length="9" /><text>phosphate</text></annotation><annotation id="3994"><infon key="identifier">MESH:D000431</infon><infon key="type">Chemical</infon><location offset="9218" length="7" /><text>ethanol</text></annotation><annotation id="3995"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="9034" length="8" /><text>patients</text></annotation><annotation id="3996"><infon key="identifier">MESH:D019343</infon><infon key="type">Chemical</infon><location offset="9282" length="7" /><text>citrate</text></annotation><annotation id="3997"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="9048" length="2" /><text>AD</text></annotation><annotation id="3998"><infon key="identifier">MESH:D005557</infon><infon key="type">Chemical</infon><location offset="8935" length="12" /><text>Formaldehyde</text></annotation><annotation id="3999"><infon key="identifier">MESH:D000067329</infon><infon key="type">Disease</infon><location offset="9057" length="2" /><text>HC</text></annotation><annotation id="4000"><infon key="identifier">MESH:D014992</infon><infon key="type">Chemical</infon><location offset="9193" length="6" /><text>xylene</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9315</offset><text>Slides were blocked with 10% donkey serum (cat. no. D9663, Sigma-Aldrich, St. Louis, MO, USA) prior to staining with polyclonal rabbit anti-OX40 (cat. no. 119904) and monoclonal mouse anti-OX40L (cat. no. Ab89896, clone: MM0505-8S23) both from Abcam, Cambridge, UK (16 mug/ml). Another set-up was made with monoclonal rabbit anti-tryptase (cat. no. ab134932, clone: EPR8476, Abcam) (7 mug/ml) and monoclonal mouse anti-OX40L, as mentioned above. All antibodies were analysed for optimal working concentration. Slides were incubated with primary antibodies overnight at 4 C. The slides were washed and donkey anti-mouse Alexa 488 (cat. no. 715-546-151, JIR) and donkey anti-rabbit Alexa 647 (cat. no. 711-606-152, JIR) secondary antibodies (both 7.5 mug/ml) were added together with DAPI (AppliChem GmbH, Darmstadt, Germany) (1 mug/ml) and incubated for 30 min. For negative control of unspecific binding, a mouse IgG1 isotype control (cat. no. X0931, DAKO, Glostrup, Denmark) was used. The slides were washed, all sections subsequently fixed with Mounting Medium (DAKO), and analysed by confocal microscopy (LSM710, Zeiss, Oberkochen, Germany).</text><annotation id="4001"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="9455" length="4" /><text>OX40</text></annotation><annotation id="4002"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="9504" length="5" /><text>OX40L</text></annotation><annotation id="4003"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="9655" length="3" /><text>cat</text></annotation><annotation id="4004"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="9734" length="5" /><text>OX40L</text></annotation><annotation id="4005"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="10250" length="3" /><text>cat</text></annotation><annotation id="4006"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="10006" length="3" /><text>cat</text></annotation><annotation id="4007"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="9945" length="3" /><text>cat</text></annotation><annotation id="4008"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="9511" length="3" /><text>cat</text></annotation><annotation id="4009"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="9461" length="3" /><text>cat</text></annotation><annotation id="4010"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="9358" length="3" /><text>cat</text></annotation><annotation id="4011"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="10222" length="5" /><text>mouse</text></annotation><annotation id="4012"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="9367" length="5" /><text>D9663</text></annotation><annotation id="4014"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="9664" length="8" /><text>ab134932</text></annotation><annotation id="4016"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="9559" length="5" /><text>Abcam</text></annotation><annotation id="4018"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="9723" length="5" /><text>mouse</text></annotation><annotation id="4019"><infon key="identifier">MESH:C007293</infon><infon key="type">Chemical</infon><location offset="10097" length="4" /><text>DAPI</text></annotation><annotation id="4021"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="9681" length="7" /><text>EPR8476</text></annotation><annotation id="4023"><infon key="identifier">MESH:C569686</infon><infon key="type">Chemical</infon><location offset="9995" length="9" /><text>Alexa 647</text></annotation><annotation id="4024"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="9934" length="9" /><text>Alexa 488</text></annotation><annotation id="4025"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="9690" length="5" /><text>Abcam</text></annotation><annotation id="4027"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="9493" length="5" /><text>mouse</text></annotation><annotation id="4028"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="9928" length="5" /><text>mouse</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>10461</offset><text>Statistical analyses</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10482</offset><text>Statistical analyses and graphs were done using Prism 6 (GraphPad Software, La Jolla CA USA). Unpaired data were analysed using the Mann-Whitney rank sum test, and paired data were analysed using the Wilcoxon signed-rank test. Correlations were tested using Spearman's rho (rho). Graphics are presented as medians with 10th to 90th percentiles and interquartile range (IQR), unless otherwise specified. A 2-sided p-value &lt; 0.05 was considered statistically significant.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>10953</offset><text>RESULTS</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>10961</offset><text>Serum levels of sOX40, but not of sOX40L, are decreased in atopic dermatitis</text><annotation id="4029"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="11020" length="17" /><text>atopic dermatitis</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>11038</offset><text>Serum levels of sOX40 and sOX40L were measured in patients with AD (67 adults and 60 children) and healthy adult volunteers (HC) (n = 31) (Table I). In adult patients with AD, sOX40 was significantly reduced (9.1; range 2.0-26.0 pg/ml) compared with HC (15.6; 3.7-32.3 pg/ ml) (p &lt; 0.0001). In children with AD, sOX40 levels were comparable with adult AD levels (9.7; 2.0-24.6 pg/ml) (Fig. 1A). Regarding sOX40L, no significant differences were observed between the groups (Fig. 1B).</text><annotation id="4030"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="11390" length="2" /><text>AD</text></annotation><annotation id="4031"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="11102" length="2" /><text>AD</text></annotation><annotation id="4032"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="11196" length="8" /><text>patients</text></annotation><annotation id="4033"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="11346" length="2" /><text>AD</text></annotation><annotation id="4034"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="11088" length="8" /><text>patients</text></annotation><annotation id="4035"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="11210" length="2" /><text>AD</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>11528</offset><text>Serum levels of sOX40 is associated with atopic comorbidities and in children with disease activity</text><annotation id="4036"><infon key="identifier">MESH:C566404</infon><infon key="type">Disease</infon><location offset="11569" length="6" /><text>atopic</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>11628</offset><text>Significantly different levels of serum sOX40 were observed between the groups; therefore we examined the association between the individual serum sOX40 level, the SCORAD index, and other markers related to atopic disease activity. In the group of adults with AD, the patients with asthma had significant higher sOX40 serum levels (10.0; range 4.0-12.8 pg/ml), compared with those without asthma (7.0; 4.6-10.2 pg/ml) (p &lt; 0.01). In children, sOX40 correlated with SCORAD (rho = 0.404, p &lt; 0.01) (Table II). Soluble OX40L showed no association with disease activity measurements, either in children or in adults.</text><annotation id="4037"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="12144" length="5" /><text>OX40L</text></annotation><annotation id="4038"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="11896" length="8" /><text>patients</text></annotation><annotation id="4039"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="11910" length="6" /><text>asthma</text></annotation><annotation id="4040"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="11888" length="2" /><text>AD</text></annotation><annotation id="4041"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="12017" length="6" /><text>asthma</text></annotation><annotation id="4042"><infon key="identifier">MESH:D006969</infon><infon key="type">Disease</infon><location offset="11835" length="14" /><text>atopic disease</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>12244</offset><text>OX40 and OX40L are highly expressed by skin-homing T cells and monocytes in atopic dermatitis</text><annotation id="4043"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="12244" length="4" /><text>OX40</text></annotation><annotation id="4044"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="12253" length="5" /><text>OX40L</text></annotation><annotation id="4045"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="12320" length="17" /><text>atopic dermatitis</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12338</offset><text>Considering the reduced sOX40 serum levels in patients with AD, we investigated the surface expression of OX40 and its ligand on PBMCs from adult patients with AD. Immunophenotyping of PBMCs from adult patients with AD (n = 11) and HC (n = 10) revealed that OX40 was mainly expressed by skin-homing memory-prone CLA+ T cells, in both AD patients and HC (Fig. 2A and B).</text><annotation id="4046"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="12444" length="4" /><text>OX40</text></annotation><annotation id="4047"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="12596" length="4" /><text>OX40</text></annotation><annotation id="4048"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="12675" length="8" /><text>patients</text></annotation><annotation id="4049"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="12498" length="2" /><text>AD</text></annotation><annotation id="4050"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="12398" length="2" /><text>AD</text></annotation><annotation id="4051"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="12484" length="8" /><text>patients</text></annotation><annotation id="4052"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="12384" length="8" /><text>patients</text></annotation><annotation id="4053"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="12554" length="2" /><text>AD</text></annotation><annotation id="4054"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="12672" length="2" /><text>AD</text></annotation><annotation id="4055"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="12540" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12708</offset><text>In adult patients with AD, 8.9% (6.8-14.2%) of the CD4+CD45RO+CLA+ T cells expressed OX40 followed by 4.6% (3.4-6.6%) of the CD4+CD45RO+CLA- T cells. OX40 expression in AD patients was less pronounced on CD8+CD45RO+CLA+ T cells (0.5%; 0.0-2.6%) and CD8+CD45RO+CLA- T cells (0.7%; 0.4-1.3%)). No differences were observed compared with HC (Fig. 2A).</text><annotation id="4056"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="12759" length="3" /><text>CD4</text></annotation><annotation id="4057"><infon key="identifier">5788</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2126</infon><location offset="12763" length="6" /><text>CD45RO</text></annotation><annotation id="4058"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="12793" length="4" /><text>OX40</text></annotation><annotation id="4059"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="12833" length="3" /><text>CD4</text></annotation><annotation id="4060"><infon key="identifier">5788</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2126</infon><location offset="12837" length="6" /><text>CD45RO</text></annotation><annotation id="4061"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="12858" length="4" /><text>OX40</text></annotation><annotation id="4062"><infon key="identifier">925</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">133777</infon><location offset="12912" length="3" /><text>CD8</text></annotation><annotation id="4063"><infon key="identifier">5788</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2126</infon><location offset="12916" length="6" /><text>CD45RO</text></annotation><annotation id="4064"><infon key="identifier">925</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">133777</infon><location offset="12957" length="3" /><text>CD8</text></annotation><annotation id="4065"><infon key="identifier">5788</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2126</infon><location offset="12961" length="6" /><text>CD45RO</text></annotation><annotation id="4066"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="12717" length="8" /><text>patients</text></annotation><annotation id="4067"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="12731" length="2" /><text>AD</text></annotation><annotation id="4068"><infon key="identifier">MESH:C000626784</infon><infon key="type">Chemical</infon><location offset="12968" length="3" /><text>CLA</text></annotation><annotation id="4069"><infon key="identifier">MESH:C000626784</infon><infon key="type">Chemical</infon><location offset="12923" length="3" /><text>CLA</text></annotation><annotation id="4070"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="12880" length="8" /><text>patients</text></annotation><annotation id="4071"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="12877" length="2" /><text>AD</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">t0002.xml</infon><infon key="id">t0002</infon><infon key="type">table_caption</infon><offset>13069</offset><text>Correlation between baseline serum levels of sOX40 in atopic dermatitis and clinical parameters</text><annotation id="4072"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="13123" length="17" /><text>atopic dermatitis</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">t0002.xml</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt; &lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align="center" rowspan="1" colspan="1"/&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;Adults&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;Children&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;SCORAD&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.096&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt; &lt;bold&gt;0.404&lt;/bold&gt; &lt;xref rid="tfn0002" ref-type="table-fn"&gt;**&lt;/xref&gt; &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;IgE&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;-0.036&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.198&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; </infon><infon key="id">t0002</infon><infon key="type">table</infon><offset>13165</offset><text> Adults Children   SCORAD 0.096 0.404**   IgE -0.036 0.198   </text><annotation id="4073"><infon key="identifier">3497</infon><infon key="type">Gene</infon><location offset="13207" length="3" /><text>IgE</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">t0002.xml</infon><infon key="id">t0002</infon><infon key="type">table_footnote</infon><offset>13229</offset><text>Correlations between serum levels of sOX40 in atopic dermatitis and disease parameters subjective SCORing Atopic Dermatitis (SCORAD) and total serum immunoglobulin E (IgE) levels. Data are analysed by Spearman correlations and values are shown as Spearman's rho (rho).</text><annotation id="4074"><infon key="identifier">3497</infon><infon key="type">Gene</infon><location offset="13378" length="16" /><text>immunoglobulin E</text></annotation><annotation id="4075"><infon key="identifier">3497</infon><infon key="type">Gene</infon><location offset="13396" length="3" /><text>IgE</text></annotation><annotation id="4076"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="13335" length="17" /><text>Atopic Dermatitis</text></annotation><annotation id="4077"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="13275" length="17" /><text>atopic dermatitis</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">t0002.xml</infon><infon key="id">t0002</infon><infon key="type">table_footnote</infon><offset>13499</offset><text>Represent level of significance: *p &lt; 0.05, **p &lt; 0.01.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>13555</offset><text>A similar pattern emerged when the results were evaluated using median fluorescence intensity (MFI), although with important differences: CD4+CD45RO+CLA+ T cells from patients with AD expressed the highest amount of OX40 per cell (MFI 287 (244-317)), and revealed a significantly higher level than HC (MFI 235; range 215-275) (p &lt; 0.05). CD4+CD45RO+CLA- T cells expressed a lower amount of OX40 (MFI 246; range 238-299), but also significantly higher than HC (MFI 214 (206-231)) (p &lt; 0.05) (Fig. 2B). A similar pattern was observed for the CD8+ T cells, but to a lesser degree than by CD4+ T cells. In general, monocytes expressed high levels of OX40L both in percentage (64.1%; range 8.1-92.1%) and MFI (1964; range 244-3649) (Fig. 2C and D), but no differences were observed between AD and HC (all p &gt; 0.05).</text><annotation id="4078"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="13693" length="3" /><text>CD4</text></annotation><annotation id="4079"><infon key="identifier">5788</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2126</infon><location offset="13697" length="6" /><text>CD45RO</text></annotation><annotation id="4080"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="13771" length="4" /><text>OX40</text></annotation><annotation id="4081"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="13893" length="3" /><text>CD4</text></annotation><annotation id="4082"><infon key="identifier">5788</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2126</infon><location offset="13897" length="6" /><text>CD45RO</text></annotation><annotation id="4083"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="13945" length="4" /><text>OX40</text></annotation><annotation id="4084"><infon key="identifier">925</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">133777</infon><location offset="14095" length="3" /><text>CD8</text></annotation><annotation id="4085"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="14140" length="3" /><text>CD4</text></annotation><annotation id="4086"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="14201" length="5" /><text>OX40L</text></annotation><annotation id="4087"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="14340" length="2" /><text>AD</text></annotation><annotation id="4088"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="13736" length="2" /><text>AD</text></annotation><annotation id="4089"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="13722" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>14380</offset><text>Cellular expression of OX40 in patients with atopic dermatitis inversely correlates with SCORAD</text><annotation id="4090"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="14403" length="4" /><text>OX40</text></annotation><annotation id="4091"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="14411" length="8" /><text>patients</text></annotation><annotation id="4092"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="14425" length="17" /><text>atopic dermatitis</text></annotation><annotation id="4093"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="14469" length="6" /><text>SCORAD</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>14476</offset><text>To further evaluate OX40 in AD, the relative cell populations were correlated with disease activity (SCORAD) and serum IgE. The percentage of CD4+CD45RO+OX40+ CLA+/- T cells correlated inversely with disease activity measured by SCORAD (CLA+ (rho = -0.809, p &lt; 0.01) and CLA- (rho = -0.782, p &lt; 0.01)). Similarly, the MFI also correlated with SCORAD (CLA+ (rho = -0.709, p &lt; 0.1) and CLA- (rho = -0.674, p &lt; 0.05)), but not with serum IgE levels. No correlations with disease activity and serum IgE for OX40 expressed by CD8+CD45RO+ CLA+/- T cells or OX40L expressed by monocytes were observed. Individual plasma levels of sOX40 and sOX40L did not correlate with surface expression of OX40 and OX40L (data not shown).</text><annotation id="4094"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="14496" length="4" /><text>OX40</text></annotation><annotation id="4095"><infon key="identifier">3497</infon><infon key="type">Gene</infon><location offset="14595" length="4" /><text>IgE.</text></annotation><annotation id="4096"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="14618" length="3" /><text>CD4</text></annotation><annotation id="4097"><infon key="identifier">5788</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2126</infon><location offset="14622" length="6" /><text>CD45RO</text></annotation><annotation id="4098"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="14629" length="4" /><text>OX40</text></annotation><annotation id="4099"><infon key="identifier">3497</infon><infon key="type">Gene</infon><location offset="14911" length="3" /><text>IgE</text></annotation><annotation id="4100"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="14979" length="4" /><text>OX40</text></annotation><annotation id="4101"><infon key="identifier">925</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">133777</infon><location offset="14997" length="3" /><text>CD8</text></annotation><annotation id="4102"><infon key="identifier">5788</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2126</infon><location offset="15001" length="6" /><text>CD45RO</text></annotation><annotation id="4103"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="15027" length="5" /><text>OX40L</text></annotation><annotation id="4104"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="15161" length="4" /><text>OX40</text></annotation><annotation id="4105"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="15170" length="5" /><text>OX40L</text></annotation><annotation id="4106"><infon key="identifier">3497</infon><infon key="type">Gene</infon><location offset="14971" length="3" /><text>IgE</text></annotation><annotation id="4107"><infon key="identifier">MESH:C000626784</infon><infon key="type">Chemical</infon><location offset="14860" length="3" /><text>CLA</text></annotation><annotation id="4108"><infon key="identifier">MESH:C000626784</infon><infon key="type">Chemical</infon><location offset="14827" length="3" /><text>CLA</text></annotation><annotation id="4109"><infon key="identifier">MESH:C000626784</infon><infon key="type">Chemical</infon><location offset="14747" length="3" /><text>CLA</text></annotation><annotation id="4110"><infon key="identifier">MESH:C000626784</infon><infon key="type">Chemical</infon><location offset="14635" length="3" /><text>CLA</text></annotation><annotation id="4111"><infon key="identifier">MESH:C000626784</infon><infon key="type">Chemical</infon><location offset="14713" length="3" /><text>CLA</text></annotation><annotation id="4112"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="14504" length="2" /><text>AD</text></annotation></passage><passage><infon key="section_type">FIG</infon><infon key="file">ActaDV-100-6-5712-g001.jpg</infon><infon key="id">f0001</infon><infon key="type">fig_caption</infon><offset>15204</offset><text>Decreased serum levels of sOX40, but not sOX40L, in atopic dermatitis (AD). Serum levels of soluble (s)OX40 and sOX40L were measured in patients with AD (adults n = 67 and children n = 60) and healthy controls (HC) (n = 31) matched for age and sex with AD adults, by enzyme-linked immunoassay (ELISA). (a) In adult patients with AD, serum levels of sOX40 were significantly decreased compared with HC. In children with AD, serum level of sOX40 showed similar levels as in adults with AD. (b) Serum levels of soluble OX40L showed no significant differences between the patients with AD and HC. Data are analysed by Mann-Whitney U test. Boxes indicate median and interquartile range (IQR) and whiskers indicate 10-90 percentiles. The dotted horizontal line indicates the ELISA cut-off value. ****p &lt; 0.0001.</text><annotation id="4113"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="15307" length="4" /><text>OX40</text></annotation><annotation id="4114"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="15720" length="5" /><text>OX40L</text></annotation><annotation id="4115"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="15457" length="2" /><text>AD</text></annotation><annotation id="4116"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="15688" length="2" /><text>AD</text></annotation><annotation id="4117"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="15772" length="8" /><text>patients</text></annotation><annotation id="4118"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="15519" length="8" /><text>patients</text></annotation><annotation id="4119"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="15256" length="17" /><text>atopic dermatitis</text></annotation><annotation id="4120"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="15786" length="2" /><text>AD</text></annotation><annotation id="4121"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="15623" length="2" /><text>AD</text></annotation><annotation id="4122"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="15275" length="2" /><text>AD</text></annotation><annotation id="4123"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="15354" length="2" /><text>AD</text></annotation><annotation id="4124"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="15533" length="2" /><text>AD</text></annotation><annotation id="4125"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="15340" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">FIG</infon><infon key="file">ActaDV-100-6-5712-g002.jpg</infon><infon key="id">f0002</infon><infon key="type">fig_caption</infon><offset>16012</offset><text>CD4+CD45RO+CLA+ T cells express high levels of OX40 in atopic dermatitis (AD), whereas OX40L is expressed primarily by monocytes. Membrane expression of OX40 and OX40L on peripheral blood mononuclear cells from patients with AD (n = 11) and healthy controls (HC) (n = 10), divided into CD4+CD45RO+ and CD8+CD45RO+ T cells with or without the expression of cutaneous lymphocyte-associated antigen (CLA). (a): OX40 was expressed primarily by the CD4+ CD45RO+ CLA+T cell subsets. (b) Median fluorescence intensity (MFI) of OX40 was significantly higher among patients with AD compared with HC. (c, d) OX40L+ monocytes, showed no difference between patients with AD and HC (both percentage and MFI). Data were analysed as non-paired data by Mann-Whitney U test. Boxes indicate median and interquartile range, and whiskers represent 10th-90th percentiles. *p &lt; 0.05, ***p &lt; 0.001.</text><annotation id="4126"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="16012" length="3" /><text>CD4</text></annotation><annotation id="4127"><infon key="identifier">5788</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2126</infon><location offset="16016" length="6" /><text>CD45RO</text></annotation><annotation id="4128"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="16059" length="4" /><text>OX40</text></annotation><annotation id="4129"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="16099" length="5" /><text>OX40L</text></annotation><annotation id="4130"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="16165" length="4" /><text>OX40</text></annotation><annotation id="4131"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="16174" length="5" /><text>OX40L</text></annotation><annotation id="4132"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="16298" length="3" /><text>CD4</text></annotation><annotation id="4133"><infon key="identifier">5788</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2126</infon><location offset="16302" length="6" /><text>CD45RO</text></annotation><annotation id="4134"><infon key="identifier">925</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">133777</infon><location offset="16314" length="3" /><text>CD8</text></annotation><annotation id="4135"><infon key="identifier">5788</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2126</infon><location offset="16318" length="6" /><text>CD45RO</text></annotation><annotation id="4136"><infon key="identifier">6404</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2261</infon><location offset="16368" length="39" /><text>cutaneous lymphocyte-associated antigen</text></annotation><annotation id="4137"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="16420" length="4" /><text>OX40</text></annotation><annotation id="4138"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="16456" length="3" /><text>CD4</text></annotation><annotation id="4139"><infon key="identifier">5788</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2126</infon><location offset="16461" length="6" /><text>CD45RO</text></annotation><annotation id="4140"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="16532" length="4" /><text>OX40</text></annotation><annotation id="4141"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="16610" length="5" /><text>OX40L</text></annotation><annotation id="4142"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="16568" length="8" /><text>patients</text></annotation><annotation id="4143"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="16067" length="17" /><text>atopic dermatitis</text></annotation><annotation id="4144"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="16671" length="2" /><text>AD</text></annotation><annotation id="4145"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="16657" length="8" /><text>patients</text></annotation><annotation id="4146"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="16237" length="2" /><text>AD</text></annotation><annotation id="4147"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="16086" length="2" /><text>AD</text></annotation><annotation id="4148"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="16223" length="8" /><text>patients</text></annotation><annotation id="4149"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="16582" length="2" /><text>AD</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>16890</offset><text>OX40 and OX40L are co-localized in atopic dermatitis</text><annotation id="4150"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="16890" length="4" /><text>OX40</text></annotation><annotation id="4151"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="16899" length="5" /><text>OX40L</text></annotation><annotation id="4152"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="16925" length="17" /><text>atopic dermatitis</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>16943</offset><text>To confirm the involvement of OX40-OX40L interactions directly in the skin, immunofluorescence staining was carried out on involved and uninvolved skin biopsies from adult patients with AD and from HC. OX40- and OX40L-expressing cells were identified in both involved and uninvolved tissue (not shown) and found to be co-localized within the dermis (Fig. 3A). In AD skin, in particular, OX40-positive staining was present on the surface of OX40L-expressing cells (Fig. 3A). That these were indeed OX40L-expressing mast cells were confirmed by positive tryptase staining (Fig. 3B).</text><annotation id="4153"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="16973" length="4" /><text>OX40</text></annotation><annotation id="4154"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="16978" length="5" /><text>OX40L</text></annotation><annotation id="4155"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="17145" length="4" /><text>OX40</text></annotation><annotation id="4156"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="17155" length="5" /><text>OX40L</text></annotation><annotation id="4157"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="17330" length="4" /><text>OX40</text></annotation><annotation id="4158"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="17383" length="5" /><text>OX40L</text></annotation><annotation id="4159"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="17440" length="5" /><text>OX40L</text></annotation><annotation id="4160"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="17306" length="2" /><text>AD</text></annotation><annotation id="4161"><infon key="identifier">MESH:D000067329</infon><infon key="type">Disease</infon><location offset="17141" length="2" /><text>HC</text></annotation><annotation id="4162"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="17129" length="2" /><text>AD</text></annotation><annotation id="4163"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="17115" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>17524</offset><text>DISCUSSION</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>17535</offset><text>The results of this study show that children and adults with AD have reduced serum levels of sOX40 compared with adult HC. Although the patients in the study cohort were included based on their presentation of AD, some patients also had allergic rhinitis and asthma. This subsequently made it possible to examine the association of serum levels of sOX40 and sOX40L and atopic comorbidities in patients with AD.</text><annotation id="4164"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="17928" length="8" /><text>patients</text></annotation><annotation id="4165"><infon key="identifier">MESH:D065631</infon><infon key="type">Disease</infon><location offset="17772" length="17" /><text>allergic rhinitis</text></annotation><annotation id="4166"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="17671" length="8" /><text>patients</text></annotation><annotation id="4167"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="17745" length="2" /><text>AD</text></annotation><annotation id="4168"><infon key="identifier">MESH:C566404</infon><infon key="type">Disease</infon><location offset="17904" length="20" /><text>atopic comorbidities</text></annotation><annotation id="4169"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="17754" length="8" /><text>patients</text></annotation><annotation id="4170"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="17794" length="6" /><text>asthma</text></annotation><annotation id="4171"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="17942" length="2" /><text>AD</text></annotation><annotation id="4172"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="17596" length="2" /><text>AD</text></annotation><annotation id="4173"><infon key="identifier">MESH:D000067329</infon><infon key="type">Disease</infon><location offset="17654" length="2" /><text>HC</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>17946</offset><text>Previous studies have demonstrated elevated sOX40L levels in patients with active allergic asthma. This was further supported by Farres et al., who showed that increased expression of OX40L on B cells is associated with the level of total IgE in allergic asthma patients. These findings are in line with murine asthma models, in which OX40L is highly expressed by a variety of cells within the lung during an induced allergic reaction. Although, in general, decreased serum levels were observed in AD, adults with concomitant asthma had the highest levels of serum sOX40. As with all members of the TNF-super family, sOX40 can bind to its ligand expressed by different cell types. This may explain the decrease in serum levels of sOX40. However, in our experiments we observed similar levels of sOX40L in healthy volunteers and patients with AD and, thus, circulating sOX40L is not an appropriate marker of disease activity in AD.</text><annotation id="4174"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="18130" length="5" /><text>OX40L</text></annotation><annotation id="4175"><infon key="identifier">3497</infon><infon key="type">Gene</infon><location offset="18185" length="3" /><text>IgE</text></annotation><annotation id="4176"><infon key="identifier">22164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="18281" length="5" /><text>OX40L</text></annotation><annotation id="4177"><infon key="identifier">7124</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">496</infon><location offset="18545" length="3" /><text>TNF</text></annotation><annotation id="4178"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="18774" length="8" /><text>patients</text></annotation><annotation id="4179"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="18007" length="8" /><text>patients</text></annotation><annotation id="4180"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="18788" length="2" /><text>AD</text></annotation><annotation id="4181"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="18201" length="6" /><text>asthma</text></annotation><annotation id="4182"><infon key="identifier">MESH:D004342</infon><infon key="type">Disease</infon><location offset="18363" length="17" /><text>allergic reaction</text></annotation><annotation id="4183"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="18257" length="6" /><text>asthma</text></annotation><annotation id="4184"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="18472" length="6" /><text>asthma</text></annotation><annotation id="4185"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="18250" length="6" /><text>murine</text></annotation><annotation id="4186"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="18873" length="2" /><text>AD</text></annotation><annotation id="4187"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="18208" length="8" /><text>patients</text></annotation><annotation id="4188"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="18037" length="6" /><text>asthma</text></annotation><annotation id="4189"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="18444" length="2" /><text>AD</text></annotation></passage><passage><infon key="section_type">FIG</infon><infon key="file">ActaDV-100-6-5712-g003.jpg</infon><infon key="id">f0003</infon><infon key="type">fig_caption</infon><offset>18877</offset><text>OX40-and OX40L-positive cells are present in atopic dermatitis (AD) skin. (a) Skin biopsies from involved (n = 5) and uninvolved skin (n = 5) from patients with AD were examined for the presence of OX40 (red) and OX40L (green) and compared with healthy controls (n = 5). Nuclear staining was carried out by DAPI (blue). OX40- and OX40L-positive cells were present in involved and uninvolved AD skin. (b) The presence of OX40L (green) co-expressed with tryptase (red) confirmed these to be mast cells, located to the dermis of patients with AD. Original magnification x40.</text><annotation id="4190"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="18877" length="4" /><text>OX40</text></annotation><annotation id="4191"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="18886" length="5" /><text>OX40L</text></annotation><annotation id="4192"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="19075" length="4" /><text>OX40</text></annotation><annotation id="4193"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="19090" length="5" /><text>OX40L</text></annotation><annotation id="4194"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="19197" length="4" /><text>OX40</text></annotation><annotation id="4195"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="19207" length="5" /><text>OX40L</text></annotation><annotation id="4196"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="19297" length="5" /><text>OX40L</text></annotation><annotation id="4197"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="19268" length="2" /><text>AD</text></annotation><annotation id="4198"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="19024" length="8" /><text>patients</text></annotation><annotation id="4199"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="19417" length="2" /><text>AD</text></annotation><annotation id="4200"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="19038" length="2" /><text>AD</text></annotation><annotation id="4201"><infon key="identifier">MESH:C007293</infon><infon key="type">Chemical</infon><location offset="19184" length="4" /><text>DAPI</text></annotation><annotation id="4202"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="19403" length="8" /><text>patients</text></annotation><annotation id="4203"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="18922" length="17" /><text>atopic dermatitis</text></annotation><annotation id="4204"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="18941" length="2" /><text>AD</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>19450</offset><text>More interestingly, focusing on circulating skin-homing CD4+ T cells from patients with AD we observed an increase in expression of OX40. As skin-homing T cells are able to upregulate OX40 expression, an increased number of pathogenic T cells can migrate to the inflammatory site of the skin and thereby enhance local inflammation.</text><annotation id="4205"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="19506" length="3" /><text>CD4</text></annotation><annotation id="4206"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="19582" length="4" /><text>OX40</text></annotation><annotation id="4207"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="19634" length="4" /><text>OX40</text></annotation><annotation id="4208"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="19712" length="12" /><text>inflammatory</text></annotation><annotation id="4209"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="19768" length="12" /><text>inflammation</text></annotation><annotation id="4210"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="19538" length="2" /><text>AD</text></annotation><annotation id="4211"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="19524" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>19782</offset><text>In addition, this study was able to localize OX40-expressing cells to the skin of patients with AD. These cells were co-localized with mast cells, suggesting an interplay between mast cells and activated T cells through OX40-OX40L in the skin of patients with AD, and this may provide the background for part of the mechanism by which anti-OX40 therapy exerts its effect on both Eczema Area and Severity Index (EASI) score, biomarkers and skin thickness when used as treatment for AD.</text><annotation id="4212"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="19827" length="4" /><text>OX40</text></annotation><annotation id="4213"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="20002" length="4" /><text>OX40</text></annotation><annotation id="4214"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="20007" length="5" /><text>OX40L</text></annotation><annotation id="4215"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="20122" length="4" /><text>OX40</text></annotation><annotation id="4216"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="20263" length="2" /><text>AD</text></annotation><annotation id="4217"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="19878" length="2" /><text>AD</text></annotation><annotation id="4218"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="20028" length="8" /><text>patients</text></annotation><annotation id="4219"><infon key="identifier">MESH:D004485</infon><infon key="type">Disease</infon><location offset="20161" length="6" /><text>Eczema</text></annotation><annotation id="4220"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="20042" length="2" /><text>AD</text></annotation><annotation id="4221"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="19864" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>20267</offset><text>Together, these findings indicate a close correlation between the OX40 system and atopic diseases.</text><annotation id="4222"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="20333" length="4" /><text>OX40</text></annotation><annotation id="4223"><infon key="identifier">MESH:D006969</infon><infon key="type">Disease</infon><location offset="20349" length="15" /><text>atopic diseases</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>20366</offset><text>In conclusion, OX40 expression is increased on skinhoming T cells and, together with our finding that OX40 and OX40L are co-localized in the skin, the OX40-OX40L system may play an important role in the recruitment to and activation of these cells in the skin. This finding is supported by the association of disease activity and atopic co-morbidities in atopic dermatitis, and we hypothesize that the OX40 system plays a pivotal role in the inflammatory reaction in the skin. It is therefore of interest to follow the development of AD treatments targeting the OX40 system.</text><annotation id="4224"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="20381" length="4" /><text>OX40</text></annotation><annotation id="4225"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="20468" length="4" /><text>OX40</text></annotation><annotation id="4226"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="20477" length="5" /><text>OX40L</text></annotation><annotation id="4227"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="20517" length="4" /><text>OX40</text></annotation><annotation id="4228"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="20522" length="5" /><text>OX40L</text></annotation><annotation id="4229"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="20768" length="4" /><text>OX40</text></annotation><annotation id="4230"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="20928" length="4" /><text>OX40</text></annotation><annotation id="4231"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="20900" length="2" /><text>AD</text></annotation><annotation id="4232"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="20808" length="12" /><text>inflammatory</text></annotation><annotation id="4233"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="20721" length="17" /><text>atopic dermatitis</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">footnote</infon><offset>20941</offset><text> The authors have no conflicts of interest to declare. </text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>20997</offset><text>REFERENCES</text></passage><passage><infon key="volume">358</infon><infon key="section_type">REF</infon><infon key="fpage">1483</infon><infon key="pub-id_pmid">18385500</infon><infon key="year">2008</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="lpage">1494</infon><offset>21008</offset><text>Atopic dermatitis</text></passage><passage><infon key="volume">113</infon><infon key="section_type">REF</infon><infon key="fpage">651</infon><infon key="pub-id_pmid">14991059</infon><infon key="year">2004</infon><infon key="source">J Clin Invest</infon><infon key="type">ref</infon><infon key="lpage">657</infon><offset>21026</offset><text>New insights into atopic dermatitis</text></passage><passage><infon key="volume">9</infon><infon key="section_type">REF</infon><infon key="fpage">271</infon><infon key="pub-id_pmid">19319144</infon><infon key="year">2009</infon><infon key="source">Nat Rev Immunol</infon><infon key="type">ref</infon><infon key="lpage">285</infon><offset>21062</offset><text>The role of TNF superfamily members in T-cell function and diseases</text><annotation id="4234"><infon key="identifier">7124</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">496</infon><location offset="21074" length="3" /><text>TNF</text></annotation></passage><passage><infon key="volume">15</infon><infon key="section_type">REF</infon><infon key="fpage">445</infon><infon key="pub-id_pmid">11567634</infon><infon key="year">2001</infon><infon key="source">Immunity</infon><infon key="type">ref</infon><infon key="lpage">455</infon><offset>21130</offset><text>OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells</text><annotation id="4235"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="21130" length="4" /><text>OX40</text></annotation><annotation id="4236"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="21215" length="3" /><text>CD4</text></annotation></passage><passage><infon key="volume">165</infon><infon key="section_type">REF</infon><infon key="fpage">3043</infon><infon key="pub-id_pmid">10975814</infon><infon key="year">2000</infon><infon key="source">J Immunol</infon><infon key="type">ref</infon><infon key="lpage">3050</infon><offset>21227</offset><text>The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion</text><annotation id="4237"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="21231" length="4" /><text>OX40</text></annotation><annotation id="4238"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="21289" length="3" /><text>CD4</text></annotation></passage><passage><infon key="volume">105</infon><infon key="section_type">REF</infon><infon key="fpage">63</infon><infon key="pub-id_pmid">20510730</infon><infon key="year">2010</infon><infon key="source">Adv Immunol</infon><infon key="type">ref</infon><infon key="lpage">98</infon><offset>21339</offset><text>OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology</text><annotation id="4239"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="21344" length="4" /><text>OX40</text></annotation><annotation id="4240"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="21339" length="4" /><text>OX40</text></annotation></passage><passage><infon key="volume">16</infon><infon key="section_type">REF</infon><infon key="fpage">474</infon><infon key="pub-id_pmid">25359291</infon><infon key="year">2014</infon><infon key="source">Arthritis Res Ther</infon><infon key="type">ref</infon><infon key="lpage">482</infon><offset>21416</offset><text>Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis</text><annotation id="4241"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="21424" length="5" /><text>OX40L</text></annotation></passage><passage><infon key="volume">41</infon><infon key="section_type">REF</infon><infon key="fpage">200</infon><infon key="pub-id_pmid">22760717</infon><infon key="year">2012</infon><infon key="source">Ann Acad Med Singapore</infon><infon key="type">ref</infon><infon key="lpage">204</infon><offset>21506</offset><text>SOX40L: an important inflammatory mediator in adult bronchial asthma</text></passage><passage><infon key="volume">191</infon><infon key="section_type">REF</infon><infon key="fpage">4573</infon><infon key="pub-id_pmid">24068673</infon><infon key="year">2013</infon><infon key="source">J Immunol</infon><infon key="type">ref</infon><infon key="lpage">4580</infon><offset>21575</offset><text>Interruption of the OX40-OX40 ligand pathway in LDL receptor-deficient mice causes regression of atherosclerosis</text><annotation id="4242"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="21600" length="4" /><text>OX40</text></annotation><annotation id="4243"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="21595" length="4" /><text>OX40</text></annotation></passage><passage><infon key="volume">28</infon><infon key="section_type">REF</infon><infon key="fpage">57</infon><infon key="pub-id_pmid">20307208</infon><infon key="year">2010</infon><infon key="source">Annu Rev Immunol</infon><infon key="type">ref</infon><infon key="lpage">78</infon><offset>21688</offset><text>Control of immunity by the TNFR-related molecule OX40 (CD134)</text><annotation id="4244"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="21737" length="4" /><text>OX40</text></annotation></passage><passage><infon key="volume">33</infon><infon key="section_type">REF</infon><infon key="fpage">861</infon><infon key="pub-id_pmid">12672051</infon><infon key="year">2003</infon><infon key="source">Eur J Immunol</infon><infon key="type">ref</infon><infon key="lpage">869</infon><offset>21750</offset><text>Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma</text><annotation id="4245"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="21768" length="4" /><text>OX40</text></annotation></passage><passage><infon key="volume">173</infon><infon key="section_type">REF</infon><infon key="fpage">5247</infon><infon key="pub-id_pmid">15470070</infon><infon key="year">2004</infon><infon key="source">J Immunol</infon><infon key="type">ref</infon><infon key="lpage">5257</infon><offset>21851</offset><text>T cell proliferation by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells: comparison of gene expression profiles between human tonsillar and lung-cultured mast cells</text><annotation id="4246"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="21937" length="4" /><text>OX40</text></annotation><annotation id="4247"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="21901" length="4" /><text>OX40</text></annotation></passage><passage><infon key="volume">90</infon><infon key="section_type">REF</infon><infon key="fpage">831</infon><infon key="pub-id_pmid">21653238</infon><infon key="year">2011</infon><infon key="source">J Leukoc Biol</infon><infon key="type">ref</infon><infon key="lpage">838</infon><offset>22052</offset><text>Technical advance: soluble OX40 molecule mimics regulatory T cell modulatory activity on FcepsilonRI-dependent mast cell degranulation</text><annotation id="4248"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="22079" length="4" /><text>OX40</text></annotation></passage><passage><infon key="volume">101</infon><infon key="section_type">REF</infon><infon key="fpage">3594</infon><infon key="pub-id_pmid">12511410</infon><infon key="year">2003</infon><infon key="source">Blood</infon><infon key="type">ref</infon><infon key="lpage">3596</infon><offset>22187</offset><text>Mast cells produce interleukin-25 upon Fc epsilon RI-mediated activation</text></passage><passage><infon key="volume">176</infon><infon key="section_type">REF</infon><infon key="fpage">2238</infon><infon key="pub-id_pmid">16455980</infon><infon key="year">2006</infon><infon key="source">J Immunol</infon><infon key="type">ref</infon><infon key="lpage">2248</infon><offset>22260</offset><text>Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF</text></passage><passage><infon key="section_type">REF</infon><infon key="fpage">44</infon><infon key="issue">Suppl 92</infon><infon key="year">1980</infon><infon key="source">Acta Derm Venereol</infon><infon key="type">ref</infon><infon key="lpage">47</infon><offset>22363</offset><text>Diagnostic features of atopic dermatitis</text></passage><passage><infon key="volume">2</infon><infon key="section_type">REF</infon><infon key="fpage">263</infon><infon key="pub-id_pmid">23875127</infon><infon key="year">2013</infon><infon key="source">Springerplus</infon><infon key="type">ref</infon><infon key="lpage">268</infon><offset>22404</offset><text>A simple set of validation steps identifies and removes false results in a sandwich enzyme-linked immunosorbent assay caused by anti-animal IgG antibodies in plasma from arthritis patients</text></passage><passage><infon key="volume">32</infon><infon key="section_type">REF</infon><infon key="fpage">313</infon><infon key="pub-id_pmid">21781408</infon><infon key="year">2011</infon><infon key="source">Allergy Asthma Proc</infon><infon key="type">ref</infon><infon key="lpage">318</infon><offset>22593</offset><text>Serum OX40 ligand levels in asthmatic children: a potential biomarker of severity and persistence</text><annotation id="4249"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="22599" length="4" /><text>OX40</text></annotation></passage><passage><infon key="volume">51</infon><infon key="section_type">REF</infon><infon key="fpage">573</infon><infon key="pub-id_pmid">24580371</infon><infon key="year">2014</infon><infon key="source">J Asthma</infon><infon key="type">ref</infon><infon key="lpage">577</infon><offset>22691</offset><text>OX40 ligand: a potential costimulatory molecule in atopic asthma</text><annotation id="4250"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="22691" length="4" /><text>OX40</text></annotation></passage><passage><infon key="volume">6</infon><infon key="section_type">REF</infon><infon key="fpage">979</infon><infon key="pub-id_pmid">25093096</infon><infon key="year">2014</infon><infon key="source">J Thorac Dis</infon><infon key="type">ref</infon><infon key="lpage">987</infon><offset>22756</offset><text>The upregulated expression of OX40/OX40L and their promotion of T cells proliferation in the murine model of asthma</text><annotation id="4251"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="22786" length="4" /><text>OX40</text></annotation><annotation id="4252"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="22791" length="5" /><text>OX40L</text></annotation></passage><passage><infon key="volume">17</infon><infon key="section_type">REF</infon><infon key="fpage">4213</infon><infon key="pub-id_pmid">29344664</infon><infon key="year">2018</infon><infon key="source">Mol Med Rep</infon><infon key="type">ref</infon><infon key="lpage">4220</infon><offset>22872</offset><text>Crucial role of OX40/OX40L signaling in a murine model of asthma</text><annotation id="4253"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="22888" length="4" /><text>OX40</text></annotation><annotation id="4254"><infon key="identifier">7292</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2495</infon><location offset="22893" length="5" /><text>OX40L</text></annotation></passage><passage><infon key="volume">144</infon><infon key="section_type">REF</infon><infon key="fpage">482</infon><infon key="pub-id_pmid">30738171</infon><infon key="year">2019</infon><infon key="source">J Allergy Clin Immunol</infon><infon key="type">ref</infon><infon key="lpage">493</infon><offset>22937</offset><text>GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis</text><annotation id="4255"><infon key="identifier">7293</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2496</infon><location offset="22954" length="4" /><text>OX40</text></annotation></passage><relation id="R1"><infon key="score">0.8971</infon><infon key="role1">Gene|7293</infon><infon key="role2">Gene|920</infon><infon key="type">Positive_Correlation</infon></relation><relation id="R2"><infon key="score">0.9987</infon><infon key="role1">Disease|MESH:D003876</infon><infon key="role2">Gene|7292</infon><infon key="type">Association</infon></relation><relation id="R3"><infon key="score">0.9653</infon><infon key="role1">Gene|7292</infon><infon key="role2">Gene|7293</infon><infon key="type">Bind</infon></relation><relation id="R4"><infon key="score">0.9462</infon><infon key="role1">Disease|MESH:D006969</infon><infon key="role2">Gene|7292</infon><infon key="type">Association</infon></relation><relation id="R5"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D007249</infon><infon key="role2">Gene|7293</infon><infon key="type">Association</infon></relation><relation id="R6"><infon key="score">0.9989</infon><infon key="role1">Disease|MESH:D003876</infon><infon key="role2">Gene|7293</infon><infon key="type">Negative_Correlation</infon></relation></document>
</collection>